mapping global health partnerships what they are, what

GHP Study Paper 1:

MAPPING GLOBAL HEALTH PARTNERSHIPS What they are, what they do and where they operate This paper forms part of the 2004 DFID Study: Global Health Partnerships: Assessing the Impact.

Cindy Carlson DFID Health Resource Centre 27 Old Street London EC1V 9HL Tel: +44 (0) 207 251 9555 Fax: +44 (0) 207 251 9552

The DFID Health Resource Centre (HRC) provides technical assistance and information to the British Government’s Department for International Development (DFID) and its partners in support of pro-poor health policies, financing and services. The HRC is based at IHSD's UK offices and managed by an international consortium of five organisations: Ifakara Health Research and Development Centre, Tanzania (IHRDC); Institute for Health Sector Development, UK (IHSD Limited); ICDDR,B - Centre for Health and Population Research, Bangladesh; Sharan, India; Swiss Centre for International Health (SCIH) of the Swiss Tropical Institute, Switzerland. This report was produced by the Health Resource Centre on behalf of the Department for International Development, and does not necessarily represent the views or the policy of DFID. Title: Mapping Global Health Partnerships Author: Cindy Carlson

DFID Health Resource Centre 27 Old Street London EC1V 9HL Tel: +44 (0) 20 7251 9555 Fax: +44 (0) 20 7251 9552

Table of Contents Acronym List ........................................................................................................... 1 Abbreviations .......................................................................................................... 3 1. Introduction ...................................................................................................... 4 2. Definition of a Global Health Partnership....................................................... 5 3. A Working Typology ........................................................................................ 6 4. Global Mapping of GHPS................................................................................. 7 5. Limitations........................................................................................................ 8 Appendix A – Global Health Partnerships – Basic Information ........................... 9 Appendix B: Global Health Partnerships – Mapping by Country Exercise ..... 27 Appendix C – DFID Interest .................................................................................. 55

Mapping Global Health Partnerships 1

DFID Health Resource Centre

ACRONYM LIST AAI Accelerating Access Initiative to HIV Care ACHAP African Comprehensive HIV/AIDS Partnerships AHPSR Alliance for Health Policy and Systems Research AMD Alliance for Microbicide Development AMP African Malaria Partnership (GSK) APOC African Program for Onchocerciasis Control CF Concept Foundation CICCR Consortium for Industrial Collaboration in

Contraceptive Research CVP Children’s Vaccine Program at PATH DPP Diflucan Partnership Program DNDi Drugs for Neglected Diseases Initiative DVP Dengue Vaccine Project EL-MDRTBP Eli Lilly Multi-Drug Resistance Tuberculosis

Partnership EMVI European Malaria Vaccine Initiative FIND Foundation for Innovative New Diagnostics GAEL Global Alliance to Eliminate Leprosy GAELF Global Alliance for the Elimination of Lymphatic

Filiariasis GAIN Global Alliance for Improved Nutrition GAVI Global Alliance for Vaccines and Immunization GBC Global Business Coalition on HIV/AIDS GCM Global Campaign for Microbicides GCWA Global Coalition on Women and AIDS GET 2020 WHO Alliance for the Global Elimination of Trachoma GFATM Global Fund to Fight AIDS, TB and Malaria GFUNC Gates Foundation/U. of North Carolina Partnership for

the Development of New Drugs GMAI Global Media AIDS Initiative GMP Global Microbicide Project GOARN Global Outbreak Alert and Response Network GPEI Global Polio Eradication Initiative GPHW Global Public-Private Partnership for Hand Washing

with Soap GRI Global Reporting Initiative GWEP Guinea Worm Eradication Program HACI Hope for African Children Initiative HATC HIV/AIDS Treatment Consortium (Clinton Foundation

AIDS Initiative) HHVI Human Hookworm Vaccine Initiative HIN Health InterNetwork HTVN HIV Vaccine Trials Network IAVI International AIDS Vaccine Initiative IDRI Infectious Disease Research Institute IOWH Infectious Disease Research Institute IPAAA International Partnership Against AIDS in Africa IPM International Partnership for Microbicides ITI International Trachoma Initiative JPMW Japanese Pharmaceutical, Ministry of Health, WHO

Malaria Drug Partnership



LAPDAP Name of anti-malarial treatment developed in public-

private partnership LFI Lassa Fever Initiative MDP 1 Mectizan Donation Program MDP 2 Microbicides Development Programme MI Micronutrient Initiative MIM Multilateral Initiative on Malaria MMV Medicines for Malaria Venture MNT Campaign to Eliminate Maternal and Neo-natal

Tetanus MTCT-Plus Maternal to Child Transmission MVI Malaria Vaccine Initiative MVP Meningitis Vaccine Programme NetMark Plus (insecticide treated net social marketing programme)

PARTNERS Partnership Against Resistant Tuberculosis: A Network for Equity and Resource Strengthening

PDVI Paediatric Dengue Vaccine Initiative PneumoADIP Pneumococcal Accelerated Development and

Introduction Plan RBM Roll Back Malaria SCI Schistosomiasis Control Initiative SF Secure the Future Initiative SIGN Safe Injection Global Network Step Forward (international pharmaceutical company initiative to

support AIDS orphans) TROPIVAL (French based R&D partnership for neglected

diseases) VDP Viramune Donation Program VF Vaccine Fund Vision 2020 (global initiative to eliminate unnecessary blindness)

VITA Vitamin A Global Initiative VVM Vaccine Vial Monitors WPESS WHO Programme to Eliminate Sleeping Sickness



ABBREVIATIONS APOC African Programme for Onchocercaisis Control BPD Building Partnerships for Development CCM Country coordinating mechanism CCPP Child Care Partnership Project CEO Chief Executive Officer DAC Development Assistance Committee (OECD) DETR Dept of the Environment, Transport and the Regions DFID D Department for International Development DJSI Jones Sustainability Index DOTS Directly Observed Therapy, Short Course EPI Expanded Programme of Immunization GAEL Global Alliance to Eliminate Leprosy GAELF Global Alliance to Eliminate Lymphatic Filariasis GAIN Global Alliance to Improve Nutrition GAVI Global Alliance for Vaccines and Immunisation GDF Global TB Drug Facility GFATM Global fund to fight AIDS, Tuberculosis and Malaria GFP Global Funds and Partnerships GHP The Global Health Partnership GPEI Global Polio Eradication Initiative IAVI International AIDS Vaccine Initiative ICC Inter-agency Coordinating Committee IDA International development association IMCI Integrated Management of Childhood Illness IMO/Pieca International Maritime Organisation / International Petroleum

Industry Environmental Conservation Association

ITI International Trachoma Initiative M&E Monitoring and evaluation MIM Multilateral Initiative on Malaria MOH Ministry of Health MOU Memorandum of Understanding MSC Maritime Stewardship Council. MTEF Medium Term Expenditure Framework NGO Non-Governmental Organisation NID National immunisation day OCP Onchocerciasis Control Programme PEI Polio Eradication Initiative PEPFAR Presidents Emergency Program for Aids Relief PEST In text already PPP public-private partnerships PRSP (Interim) Poverty Reduction Strategy Paper RBM Roll Back Malaria SMART Specific, Measurable, Achievable, Realistic and Time-Bound SWAP Sector Wide Approaches TA Technical Assistance TDR Tropical Disease Research TOR Terms of Reference WEF World Economic Forum WHA World Health Assembly WHOEB WHO Executive Board



INTRODUCTION The purpose of mapping Global Health Partnerships (GHPs) is to provide a common understanding of what GHPs are, how they might be classified and how they operate. This paper explains the definition used by the project team in their work on ‘Assessing the Impact of GHPs’, outlines a classification system of GHPs to help with analysis of their impact and maps where GHPs are working globally.



1. DEFINITION OF A GLOBAL HEALTH PARTNERSHIP Previous work1 in this series defines the concept of Global Health Partnership in a broad manner:

Partnership: the key criterion is a collaborative relationship among multiple organisations in which risks and benefits are shared in pursuit of a shared goal. The focus is on more formal collaborative ventures and not exclusively on public-private partnerships, although these constitute the majority. Some important global health initiatives that are not partnerships per se, such as the World Bank’s MAP, are not included.

Health: The goal of the partnerships has to concern the redress of health problems of significance for the poor in low- and middle-income countries.

‘Global’ is interpreted to capture initiatives that extend across or transcend national boundaries. In this paper for example, APOC – the African Programme for Onchocerciasis Control – is included as a GHP addressing a neglected disease, though technically it operates only within Africa rather than globally. It forms the main operating component of the Global Partnership to Eliminate River Blindness.

The World Bank’s definition of global programs are those partnerships and related initiatives whose benefits cut across more than one region of the world, and in which the partners reach explicit agreements on objectives; agree to establish a new (formal or informal) organization; generate new products or services; and contribute dedicated resources to the program2. This is a tighter definition but can generally be applied to the GHPs covered in the study, other than the geographical limitation. See Appendix A for the full list of GHPs and their principal objectives.

1 Buse K., 2004. Global Health Partnerships: Mapping a shifting terrain. London: DFID Health Resource Centre.

2 Operations Evaluation Department, World Bank. The World Bank’s Approach to Global Programs: An Independent Evaluation. The World Bank, August 1, 2002.



2. A WORKING TYPOLOGY A number of typologies have been suggested for classifying the different GHPs (Tidewater 2003; Buse 2004). The project team considered each of these, attempting to classify nineteen GHPs of interest to DFID (see below) against these existing typologies. The classification exercise highlighted a number of problems with previous typologies.. In this study, the project team adopted a typology proposed by DFID with the following four categories to classify GHPs: • Research and Development: This includes GHPs that are involved in product

discovery and development of new therapies (vaccines, treatments etc.); • Technical assistance/service support: This includes GHPs that provide drug

donations, support improved service access and give technical assistance; • Advocacy (national and international levels): includes GHPs who advocate for

increased international and national response to specific diseases, who fund-raise for specific control programmes etc.

• Financing: includes GHPs who provide funds for specific programmes (not as donations).

GHPs have then been classified against this typology as to whether they have a primary or secondary role in these areas. See Appendix B for tables showing GHP classification. This classification is based on the stated objectives of each GHP, as well as an understanding of the modus operandi of each one.



3. GLOBAL MAPPING OF GHPS The project team also mapped where Global Health Partnerships provide support on a country by country basis, and analysed this against epidemiological and socio-economic information of these countries. The initial global mapping was done early in the project in order to inform decisions as to which countries to include in the country case study work. Key findings are that the strongest correlation for a high number of GHPs operating in a country is the region the country belongs to, with Africa having consistently the highest number of GHPs per country, followed by Asia (East, Southeast and Central). Eastern and Central European countries have the lowest number of GHPs. There appears to be a correlation between the per capita GDP and the number of GHPs operating in a country. In general, the lower the per capita GDP, the greater the number of GHPs, though this is inconsistent. There is a moderate correlation between the prevalence rate or case number of a disease and the presence of the relevant GHP, as would be expected. However, without looking at GFATM support on a country by country basis, it is impossible to assess whether appropriate levels of GFATM funding are being received by each of its three target diseases in each country where it is present, based on the epidemiology of the disease in that country, There is no apparent correlation between the number and type of GHPs operating in a country and:

- the type of government as measured on a scale of –10 (authoritarian) to +10 (fully democratic); or

- the percentage of spending on the health sector coming from the public purse.

Information from the full mapping exercise and analysis can be found in Appendix C.



4. LIMITATIONS The team encountered a number of constraints in trying to identify a useful typology as well as in mapping and analysing GHPs on a global level. These included the following: • While the list of GHPs is meant to be as exhaustive as possible, some are difficult

to identify and new ones are set up on a frequent basis. Also, there are definitional difficulties and some of the organisations included on the list in Appendix A may not fit with everyone’s interpretation of a GHP.

• GHPs are complex beasts and are not easily slotted into specific boxes on a table. Also, GHPs may change how they work depending on whether they are assessed at an international or national level. As such, the proposed classification found in Appendix B is open for further debate and discussion. For the purposes of this paper, it is their international ‘face’ that is being considered.

• The global mapping exercise focused primarily on those countries that appear to have the greatest number of active GHPs in-country. As such, not all countries have complete epidemiological or socio-economic information provided.

Mappin

g G

lobal H

ealth P

art

ners

hip

s

9

DF

ID H

ealth R

esourc

e C

entr

e

AP

PE

ND

IX A

– G

LO

BA

L H

EA

LT

H P

AR

TN

ER

SH

IPS

– B

AS

IC I

NF

OR

MA

TIO

N

Ac

ron

ym

M

issio

n,

Aim

s a

nd

/or

Ob

jecti

ves

AA

I •

To m

ake

HIV

/AID

S m

edic

ine

s in

clu

din

g t

reatm

ents

fo

r oppo

rtun

istic

infe

ction

s and a

ntir

etr

ovir

al

thera

py

and d

iagn

ost

ic

equ

ipm

ent

more

availa

ble

an

d a

fford

ab

le in t

he

ha

rde

st-

hit r

eg

ion

s o

f th

e w

orld

•

To w

ork

with g

overn

ments

, in

tern

ationa

l org

an

izatio

ns,

pri

vate

se

cto

r st

akehold

ers

, an

d o

the

rs t

o f

ind w

ays

to b

roa

de

n

acce

ss t

o c

are

wh

ile e

nsu

ring r

ation

al,

aff

ord

ab

le,

safe

and

eff

ect

ive u

se o

f dru

gs f

or

HIV

/AID

S r

ela

ted illn

esses

•

To c

oo

rdin

ate

action

an

d fa

cili

tate

neg

otiation

s w

ith a

ran

ge

of

su

pplie

rs fo

r dee

ply

dis

co

unte

d d

rug p

rice

s

AC

HA

P

ww

w.a

chap.o

rg/

•

To s

upp

ort

the

go

als

of

the

Go

vern

me

nt

of

Bots

wan

a t

o d

ecr

ea

se

HIV

in

cid

en

ce b

y ra

pid

ly a

dvan

cin

g H

IV/A

IDS

pre

vention

pro

gra

ms,

he

alth

care

access,

patie

nt

man

age

men

t and

tre

atm

ent

of

HIV

/AID

S

in

Bots

wana

in

a

su

sta

ina

ble

an

d

com

pre

he

nsi

ve m

an

ner

AH

PS

R

ww

w2.a

lliance-

hpsr.

org

/jahia

/Jahia

/cache/o

ff

•

To p

rom

ote

ca

pa

city

for

he

alth

po

licy

an

d s

yste

ms r

ese

arc

h o

n in

tern

atio

na

l is

sue

s

•

To d

eve

lop t

he

info

rma

tion

for

po

licy

de

cis

ion

s in

the h

ea

lth s

ect

or

and

oth

er

se

cto

rs w

hic

h h

ave a

be

arin

g o

n h

ealth

•

To stim

ula

te th

e ge

nera

tion

of

know

ledg

e w

hic

h fa

cilit

ate

s p

olic

y a

naly

sis

a

nd im

pro

ve

s th

e und

ers

tan

din

g of

hea

lth

sys

tem

s a

nd p

olic

y pro

cess

•

To s

tre

ngth

en inte

rnatio

na

l re

sea

rch

co

llabora

tio

n a

nd info

rmation e

xch

an

ge a

mo

ng c

ou

ntr

ies.

•

To id

entify

in

fluen

ces o

n h

ealth

sys

tem

s w

hic

h o

pera

te a

t th

e g

lob

al le

vel a

nd

pro

mote

appro

pri

ate

re

se

arc

h.

AM

D

ww

w.m

icro

bic

ide.o

rg

•

To

cata

lyse

scie

ntific p

rogre

ss, fu

nd

ing

, a

nd

po

licy

ch

ange

in t

he f

ield

of to

pic

al m

icro

bic

ide

s t

o p

reven

t se

xually

-tra

nsm

itte

d

infe

ctio

ns.

Th

e A

llian

ce w

ork

s t

o a

ch

ieve

its

mis

sio

n t

hro

ugh r

ese

arc

h,

ed

ucation,

an

d a

dvo

cacy;

netw

ork

ing a

nd c

on

venin

g

acro

ss c

on

stitu

encie

s, d

iscip

lines,

and s

ect

ors

; a

nd s

tra

teg

izin

g t

o i

den

tify

ga

ps a

nd

obsta

cle

s a

nd

work

ing t

ow

ard

the

ir

elim

ination

•

Th

e A

llia

nce

pla

ys a

sig

nific

an

t ro

le n

ot

pe

rform

ed

by

an

y o

ther

en

tity

, a

ro

le t

hat

inte

gra

tes

cata

lysis

, co

mm

unic

ation

, co

nve

nin

g,

and p

rob

lem

-so

lvin

g, a

nd a

d h

oc p

art

nerin

g a

s ne

ed

ed b

y th

e f

ield

wri

t la

rge

AM

P

ww

w.g

sk.c

om

/mala

ria

/

•

To su

pp

ort

com

mu

niti

es

thro

ug

h th

e sca

le-u

p of

eff

ective b

eha

vio

ura

l d

evelo

pm

en

t a

ctiv

itie

s w

ho

se pri

mary

fo

cu

s is

m

ala

ria

co

ntr

ol

•

To r

ais

e a

ware

ne

ss

abo

ut th

e p

reve

ntion a

nd

tre

atm

en

t of m

ala

ria

•

To im

pro

ve th

e q

ua

lity

of re

late

d h

ea

lth s

erv

ice

s

•

To e

sta

blis

h o

f a

n e

ffe

ctiv

e c

om

mu

nity-

ba

sed

sys

tem

of p

revention

AP

OC

w

ww

.worldba

nk.o

rg/a

fr/

gper/

apoc.h

tm

See

Glo

bal

Part

ners

hip

to

E

limin

ate

R

iver

Blin

dness

•

To e

limin

ate

Riv

erb

lindne

ss

as a

pu

blic

hea

lth

pro

ble

m in

all

of A

fric

a,

where

99

% o

f th

e w

orld

’s c

ase

s occur.

•

To p

rote

ct

109

mill

ion p

eop

le o

n 1

9 A

fric

an c

oun

trie

s fro

m c

ontr

act

ing b

lindin

g R

iverb

lind

ne

ss

and

dis

figu

ring

skin

dis

ea

se

•

To p

revent

43,0

00

ca

ses o

f blin

dn

ess

ann

ua

lly,

alle

via

te u

nbeara

ble

itc

hin

g a

nd

elim

inate

un

sig

htly

skin

dis

ea

se.

•

To b

uild

na

tion

al capa

city

and e

mp

ow

er

aff

ecte

d c

om

mu

niti

es t

o s

usta

inably

add

ress m

an

y dis

ease

s a

nd h

ealth issu

es

via

co

mm

un

ity-

dire

cted d

rug d

istr

ibution s

yste

ms.

•

Mappin

g G

lobal H

ealth P

art

ners

hip

s

10

DF

ID H

ealth R

esourc

e C

entr

e

Art

esunate

•

Em

erg

en

cy

tre

atm

ent

of

acute

ma

lari

a in p

atie

nts

who

can

no

t ta

ke o

ral m

ed

icatio

n a

nd f

or

whom

in

ject

ab

le t

reatm

ent

is n

ot

ava

ilab

le.

Da

ta h

as b

ee

n s

ubm

itte

d b

y W

HO

for

regu

lato

ry a

ppro

val.

WH

O in

ten

ds

whe

n a

ppro

va

l is

ob

tain

ed t

o i

nclu

de i

t on t

he W

HO

and

Natio

na

l e

ssentia

l dru

g lis

t.

Child

S

urv

ival

Part

ners

hip

w

ww

.child

surv

ivalp

art

ners

hip

.org

•

To p

rovid

e a

foru

m fo

r coord

inate

d

act

ion

to

addre

ss th

e m

ajo

r co

nditio

ns

that

aff

ect

child

ren's

he

alth,

and e

nab

le

govern

me

nts

an

d

part

ners

to

a

gre

e

on

co

nsis

tent

appro

ache

s

an

d

stim

ula

tes

con

cert

ed

e

ffort

s

tow

ard

s th

eir

imp

lem

enta

tion.

•

To

supp

ort

cou

ntr

ies

with

hig

h c

hild

mort

alit

y to

rais

e t

he p

rofile

of

child

surv

iva

l; d

evelo

p c

ou

ntr

y-le

d s

tra

teg

ies f

or

child

m

ort

alit

y re

du

ctio

n;

str

en

gth

en

coord

inatio

n,

co

mm

un

ication an

d k

now

ledge-s

ha

ring;

Mo

nitor

the pro

cess

and

eva

luate

outc

om

es of

ch

ild surv

iva

l activi

tie

s and

tr

ack th

e a

lloca

tio

n a

nd

u

se of

fina

ncia

l re

so

urc

es at

all

leve

ls;

dis

sem

ina

te

info

rmation a

nd

fa

cilit

ate

an

exch

ang

e o

f kno

wle

dg

e,

expert

ise

and r

eso

urc

es b

etw

een a

ll in

tere

ste

d p

art

ies.

CIC

CR

w

ww

.conra

d.o

rg/

•

To f

un

d r

esearc

h a

nd d

eve

lopm

en

t in

not-

for-

pro

fit re

sea

rch

institu

tio

ns w

ork

ing in

colla

bora

tio

n w

ith in

du

stri

al p

art

ners

•

To in

crea

se t

he in

vo

lvem

en

t of

ind

ustr

y in

de

ve

lop

ing n

ew

con

tra

ceptive a

gents

th

at

addre

ss t

he n

ee

ds

and p

ers

pe

ctiv

es o

f w

om

en

•

Identify

le

ad

s u

nder

investiga

tion

in n

ot-

for-

pro

fit

institu

tions,

bo

th i

n d

evelo

ped

and d

evelo

pin

g c

ou

ntr

ies,

and

encoura

ge

ind

ustr

y to

colla

bo

rate

with

CIC

CR

by

pro

vid

ing

sup

port

to

in

ve

stig

ato

rs a

t no

t-fo

r-pro

fit in

stitu

tio

ns

•

Th

e t

hre

e p

rio

rity

are

as f

or

the d

eve

lop

men

t of

new

co

ntr

ace

ptive m

eth

od

s are

: 1)

vag

ina

l m

eth

od

s th

at

pre

ven

t pre

gn

an

cy

and

se

xually

tra

nsm

itte

d in

fectio

ns

(ST

Is),

in

clud

ing H

IV/A

IDS

; 2

) m

ale

me

tho

ds;

an

d 3

) m

onth

ly m

eth

od

s f

or

wo

me

n

Coart

em

•

To

supp

ly a

new

the

rap

y fo

r dru

g r

esis

tan

t m

ala

ria a

t re

du

ced

co

st. C

o-d

eve

lop

ed b

y N

ovart

is a

nd

calle

d C

oart

em

®,

(a

com

bin

atio

n o

f a

rte

meth

er

plu

s lu

me

fan

trin

e),

th

e d

rug w

ill b

e i

ntr

od

uced

as

a f

irst

or

se

co

nd-l

ine

tre

atm

ent

for

ma

lari

a,

in

are

as w

here

tra

ditio

nal tr

ea

tment

is n

o lo

ng

er

eff

icacio

us

•

To i

mpro

ve t

reatm

ent

reg

ime

ns

in m

ala

ria-e

nde

mic

co

untr

ies.

No

vart

is w

ill s

up

ply

th

e d

rug i

n s

pecia

lly d

esig

ned p

ack

s to

fa

cili

tate

ad

here

nce

to

tre

atm

ent re

gim

ens b

y n

on-litera

tes

Concept

Foundatio

n

ww

w.c

onceptf

oundati

on.o

rg

•

Open

a

cce

ss

to

top

qua

lity

repro

du

ctiv

e-h

ea

lth

pro

du

cts

a

t lo

west

po

ssib

le

prices

thro

ug

h

focused

man

ag

em

en

t o

f in

telle

ctu

al pro

pert

y to

realiz

e m

axim

um

pu

blic

se

ctor

ben

efit

•

Imp

rovin

g availa

bili

ty of

pro

ducts

at

pre

fere

ntial

pri

ces

that

focus on

th

e re

pro

ductive

hea

lth

ne

ed

s o

f p

eo

ple

in

th

e

develo

pin

g w

orld

•

Ada

pta

tio

n a

nd t

ran

sfer

of

pro

du

ctio

n t

ech

no

log

ies

into

de

ve

lopin

g c

oun

trie

s t

o i

mpro

ve a

vaila

bili

ty o

f pro

du

cts

thro

ugh

enh

ancin

g lo

cal m

an

ufa

ctu

ring c

ap

ab

ilitie

s

•

Incr

easin

g t

he a

cce

pta

nce

and p

op

ula

rizin

g t

he u

se o

f p

rod

ucts

that

addre

ss t

he

he

alth n

eed

s of

pe

op

le i

n d

eve

lopin

g

cou

ntr

ies

CO

NR

AD

w

ww

.conra

d.o

rg/

•

To d

eve

lop b

ett

er,

safe

r an

d m

ore

acce

pta

ble

me

tho

ds

of

contr

ace

ptio

n,

esp

eci

ally

su

ita

ble

fo

r d

eve

lop

ing c

ountr

ies.

•

To e

xp

an

d t

he c

ho

ice o

f co

ntr

aceptive m

eth

ods

•

To

fo

ste

r re

se

arc

h d

eve

lop

men

t in

th

e a

reas o

f co

ntr

ace

ptive r

ese

arc

h, m

ale

meth

od

s a

nd v

agin

al m

eth

ods t

hat p

revent

the

transm

issi

on o

f H

IV/A

IDS

, pre

gn

an

cy

and

oth

er

sexua

lly t

ran

sm

itted infe

ctio

ns (

ST

Is)

CV

P

•

To e

nsure

that

all

child

ren r

ece

ive t

he

full

be

nefits

of

new

, lif

esa

vin

g v

acci

ne

s w

ith

out

undu

e d

ela

y

Mappin

g G

lobal H

ealth P

art

ners

hip

s

11

DF

ID H

ealth R

esourc

e C

entr

e

ww

w.c

hild

rensv

acc

ine

.org

/

•

To p

ut

imm

un

izatio

n a

t th

e t

op

of

the

glo

bal hea

lth a

ge

nd

a

•

To d

eve

lop n

ew

fin

an

cin

g s

olu

tio

ns

for

imm

uniz

atio

n

•

To c

olla

bora

te o

n r

ese

arc

h t

o p

rovid

e r

elia

ble

info

rmation f

or

de

cis

ion-m

akers

•

Sup

port

new

techno

log

ies

to im

pro

ve im

mun

izatio

n d

eliv

ery

. •

Targ

ets

in

clu

de

yello

w f

eve

r, H

ib,

Japan

ese e

nceph

alit

is,

rota

viru

s, a

nd

pn

eum

oco

ccu

s

DP

P

ww

w.d

iflu

canpart

ners

hip

.org

/en/w

elc

om

e

•

To

off

er

Diflu

ca

n a

ntifu

ng

al m

ed

icin

e a

t no

cha

rge

to lo

w-incom

e H

IV/A

IDS

pa

tie

nts

in t

he le

ast

de

velo

ped c

ountr

ies m

ost

in

nee

d, a

s ide

ntif

ied

by

the U

nite

d N

atio

ns

•

To r

ea

ch a

ll p

atie

nts

suffe

ring f

rom

cry

pto

co

cca

l men

ingitis

or

eso

phag

ea

l cand

idia

sis

who c

an

no

t aff

ord

tre

atm

ent

•

To t

rain

he

althca

re w

ork

ers

in o

pp

ort

un

istic

infe

ctio

ns a

nd t

he

ir a

ppro

pri

ate

dia

gn

osis

and

tre

atm

en

t •

To e

nsure

ong

oin

g m

on

itori

ng a

nd

sup

po

rt fro

m p

art

ne

r govern

men

ts

•

To w

ork

with t

he

UN

and

WH

O t

o e

nsu

re t

ha

t th

e D

iflu

can

Part

ne

rsh

ip e

xpa

nds a

nd r

ea

che

s a

s m

an

y p

atie

nts

as

is

possib

le in t

he targ

ete

d c

ou

ntr

ies

DN

Di

ww

w.d

ndi.org

/

•

Build

a n

eed

s-d

rive

n p

ort

folio

of short

, m

ed

ium

, a

nd lo

ng-t

erm

R&

D p

roje

cts

•

Rais

e a

wa

rene

ss a

bo

ut

ma

kin

g a

vaila

ble

dru

gs

for

neg

lecte

d d

ise

ases

•

Build

R&

D c

apa

city

in c

oun

trie

s w

he

re th

ese

dis

ea

se

s are

en

dem

ic

DV

P

•

Develo

pm

ent

of D

eng

ueV

ac,

a d

engu

e v

accin

e d

eve

lope

d b

y th

e U

niv

ers

ity

of

Ma

hid

ol.

•

Th

e w

orldw

ide l

icen

se f

or

pro

du

ctio

n a

nd

mark

etin

g r

ights

ha

s b

een g

iven t

o P

aste

ur

Meri

eux C

onn

aug

ht

for

20 y

ears

in

retu

rn for

a t

ech

no

log

y tr

an

sfer

fee

•

Th

e v

accin

e h

as

be

en

te

ste

d in

3 P

ha

se I

tri

als

in th

e U

SA

and

Tha

iland

•

Th

e v

accin

e is e

xpe

cted t

o b

e r

ea

dy

for

glo

bal u

se in 2

004

EL-M

DR

TB

P

•

To

share

of

dru

g m

anu

factu

ring

te

ch

no

log

y w

ith n

atio

ns m

ost

at

risk

in o

rder

to c

on

vert

the

ir e

xis

tin

g f

acili

tie

s to

pro

du

ce

capre

om

ycin

an

d c

yclo

seri

ne

•

To t

rain

in

pre

ve

ntio

n, tr

ea

tment

and

su

rve

illa

nce

•

To d

eve

lop jo

intly

with t

he W

HO

and

the I

nte

rnatio

na

l U

nio

n A

ga

inst

Tu

berc

ulo

sis

an

d L

ung D

ise

ase

gu

ide

lines

for

nu

rse

s fo

r tr

eating

TB

and

MD

R-T

B a

round

the w

orl

d

•

To in

crea

se

dru

g s

upp

ly a

nd d

isco

unting p

rice (

the v

alu

e o

f th

is d

iscou

nt is

appro

xim

ate

ly $

25

mill

ion (

US

D).

EM

VI

ww

w.e

mvi.o

rg/

•

To c

ontr

ibu

te t

o t

he g

loba

l e

ffort

s t

o c

on

tro

l m

ala

ria b

y pro

vid

ing a

me

cha

nis

m f

or

acce

lera

ted d

evelo

pm

ent

an

d c

linic

al

tria

ls o

f m

ala

ria v

acci

ne

s

•

To p

rom

ote

affo

rdab

ility

an

d a

cce

ssib

ility

of

ma

laria v

acc

ines

in D

evelo

pin

g C

ou

ntr

ies.

•

To b

ridg

e th

e con

ce

ptu

al

an

d op

era

tiona

l ga

ps b

etw

een th

e be

nch

pro

duct

- i.e

. ca

nd

ida

te m

ole

cu

les -

and fu

rth

er

valid

atio

n,

limited

pro

ductio

n a

nd c

linic

al t

estin

g, th

us

makin

g furt

he

r in

du

str

ial de

velo

pm

en

t an

d p

rodu

ctio

n f

easib

le

•

To f

un

d r

esearc

h a

nd d

eve

lopm

en

t, in

clud

ing c

linic

al tr

ials

, w

ith a

supra

natio

nal fo

cu

s

•

To

cre

ate

a t

echn

ica

l a

nd

fin

an

cia

l en

viron

ment

in w

hic

h p

ote

ntia

l m

ala

ria

va

ccin

es c

an b

e b

rou

gh

t to

clin

ical

tria

ls i

n

hum

an

s

•

To i

mpro

ve

the f

low

of

info

rmation b

etw

een

th

e E

uro

pean

scie

ntific c

om

mu

nity,

part

ne

rs i

n D

eve

lopin

g C

ou

ntr

ies,

re

leva

nt

Mappin

g G

lobal H

ealth P

art

ners

hip

s

12

DF

ID H

ealth R

esourc

e C

entr

e

org

an

isa

tion

s/in

stitu

tion

s, a

nd v

accin

e m

an

ufa

cture

rs (

pri

vate

and

pu

blic

), in o

rder

to fa

cili

tate

co

-op

era

tion

•

To p

rovid

e a

fo

rum

to e

nh

ance

ge

nera

l an

d p

olit

ica

l a

ware

ness

of

the im

port

an

ce o

f co

ntr

olli

ng

mala

ria

•

To

pro

vid

e a

foru

m f

or

the E

C a

nd

EU

Me

mb

er

Sta

tes R

esearc

h a

nd

De

ve

lopm

ent

Min

istr

ies/

Age

ncie

s fo

r consulta

tion

on

th

e r

ole

and

de

ve

lop

me

nt o

f m

ala

ria v

accin

es

in t

he

wid

er

co

nte

xt o

f m

ala

ria

co

ntr

ol

Mappin

g G

lobal H

ealth P

art

ners

hip

s

13

DF

ID H

ealth R

esourc

e C

entr

e

FIN

D

ww

w.f

inddia

gnostics

.org

•

To a

cce

lera

te t

he d

eve

lop

ment, e

valu

ation,

an

d a

ppro

priate

use

of

hig

h-q

ua

lity

yet

aff

ord

able

dia

gn

ost

ic t

ools

fo

r in

fectio

us

dis

ea

ses

in d

eve

lop

ing c

ou

ntr

ies (

initia

l fo

cus o

n T

B)

•

To d

eve

lop d

iagn

ostic ap

pro

ache

s th

at

have

bee

n pro

ve

n in

pri

ncip

le an

d tr

ansfo

rm th

em

in

to effe

ctive p

rodu

cts,

in

part

ners

hip

with

acad

em

ia,

pub

lic a

nd p

riva

te r

esea

rch

institu

tes a

nd in

du

stry

•

To c

om

pa

re a

nd e

va

luate

th

ese

pro

du

cts

in

coord

ina

ted labora

tory

an

d fie

ld t

rials

•

To d

em

on

str

ate

th

e im

pa

ct

of th

ese im

pro

ved

too

ls o

n d

isea

se c

ontr

ol

GA

EL

ww

w.w

ho.int/le

p/

•

To m

ake a

con

cert

ed a

nd c

oord

inate

d e

ffo

rt t

o a

chie

ve t

he e

limin

atio

n o

f le

pro

sy

as a

pu

blic

he

alth p

rob

lem

fro

m e

very

end

em

ic c

ou

ntr

y, a

t th

e n

atio

nal le

vel b

y 2

005

•

To e

nsure

th

at

all

lepro

sy

patie

nts

, w

here

ver

the

y m

ay

live

, an

d h

ow

eve

r poo

r, h

ave f

ree a

nd e

qu

al

acce

ss

to t

he m

ost

modern

of

treatm

ent

ava

ilab

le

GA

ELF

w

ww

.fila

riasi

s.org

/

•

To r

edu

ce,

inte

rrup

t and

elim

inate

tra

nsm

issi

on

of

lym

pha

tic fila

riasis

•

To

red

uce,

alle

via

te a

nd

pre

ven

t m

orb

idity

(su

fferi

ng

and

dis

ab

ility

) in

affe

cte

d i

nd

ivid

ua

ls t

hro

ugh

th

e u

se o

f A

lbe

nd

azo

le,

pro

vid

e a

dew

orm

ing b

en

efit

to e

ndem

ic p

opu

latio

ns

•

To p

rovid

e s

tre

ngth

enin

g b

enefits

to t

he h

ea

lth

serv

ice

s

GA

IN

ww

w.g

ain

health.o

rg/

•

To s

up

port

foo

d f

ort

ific

atio

n a

nd o

ther

su

sta

inab

le n

utr

itio

n s

tra

teg

ies

in o

rde

r to

sa

ve liv

es a

nd im

pro

ve h

ealth

, pro

ductivity,

and

co

gnitiv

e f

un

ction

.

•

To im

pro

ve th

e m

icro

nu

trie

nt st

atu

s o

f in

div

idu

als

liv

ing in

de

ve

lop

ing

cou

ntr

ies

•

To

supp

ort

develo

pin

g c

ou

ntr

ies

in f

oo

d f

ort

ifica

tion e

ffo

rts,

un

de

rtake

n i

n t

he c

onte

xt

of

bro

ade

r m

icro

nutr

ien

t str

ate

gie

s,

that

will

re

duce

mic

ron

utr

ient

maln

utr

itio

n

in

de

velo

pin

g

co

un

trie

s,

pa

rtic

ula

rly

thro

ug

h

incr

eased

co

nsu

mptio

n

of

mic

ronu

trie

nt-

rich fo

od

s.

GA

TB

DD

w

ww

.tballi

ance.o

rg

•

To a

ccele

rate

th

e d

isco

very

and/o

r de

velo

pm

en

t o

f co

st-

eff

ect

ive n

ew

dru

gs

that:

1.

Sh

ort

en o

r si

mplif

y tr

ea

tmen

t of

TB

, 2

. P

rovid

e e

ffective

tre

atm

ent

of

mu

lti-d

rug-r

esis

tant

TB

, 3.

Imp

rove t

he t

rea

tme

nt

of

late

nt

TB

infe

ction

, an

d 4

. C

an

be m

ade

affo

rda

ble

an

d a

cce

ssib

le in T

B e

nd

em

ic c

oun

trie

s

GA

VI

•

Mis

sio

n: to

protect children of all nations and of all socioeconomic levels against vaccine-preventable diseases

• Improve access to sustainable immunization services

• Expand the use of all existing safe and cost-effective vaccines, and promote delivery of other appropriate

interventions at immunization contacts

• Support the national and international accelerated disease control targets for vaccine-preventable diseases

• Accelerate the development and introduction of new vaccines and technologies

• Accelerate R&D efforts for vaccines needed primarily in developing countries

• Make immunization coverage a centerpiece in international development efforts

Mappin

g G

lobal H

ealth P

art

ners

hip

s

14

DF

ID H

ealth R

esourc

e C

entr

e

GB

C

ww

w.b

usin

essfig

hts

ai

ds.o

rg/

•

Incr

ease

sig

nific

antly

the

num

be

r of

com

pa

nie

s co

mm

itte

d t

o t

ack

ling A

IDS

, a

nd t

o m

ake b

usin

ess a

va

lue

d p

art

ner

in t

he

glo

ba

l eff

ort

s aga

inst

the e

pid

em

ic

•

Imp

lem

entin

g p

reventio

n a

nd c

are

pro

gra

ms a

nd p

olic

ies for

em

plo

yee

s and im

media

te c

om

mu

nitie

s

•

Brin

gin

g b

usin

ess

core

str

ength

s o

f cre

ativity

an

d f

lexib

ility

to

im

pro

ve t

he

re

ach

an

d e

ffe

ctive

ne

ss

of

AID

S p

rogra

ms

•

Lea

ders

hip

an

d a

dvo

cacy

by

bu

sin

ess

le

ade

rs,

lob

byin

g f

or

gre

ate

r actio

n a

nd p

art

ners

hip

s w

ith g

ove

rnm

ents

an

d c

ivil

soci

eties

GC

M

ww

w.g

lobal-

cam

paig

n.o

rg/

•

Rais

e a

ware

ne

ss

and

mo

bili

ze p

olit

ica

l su

pport

fo

r in

cre

ase

d f

und

ing f

or

mic

rob

icid

e r

ese

arc

h,

fem

ale

cond

om

an

d c

erv

ical

barr

ier

meth

od

s

•

Cre

ate

a s

up

po

rtiv

e p

olic

y environ

men

t fo

r th

e t

imely

develo

pm

en

t, in

tro

du

ction

an

d u

se o

f n

ew

pre

ven

tio

n t

ech

no

log

ies

•

En

sure

tha

t a

s sc

ience p

rocee

ds,

the p

ub

lic inte

rest

is p

rote

cted a

nd t

he r

ights

and inte

rests

of

tria

l pa

rtic

ipan

ts,

use

rs,

an

d

com

mu

nitie

s a

re fu

lly r

epre

sen

ted a

nd

respe

cte

d

GC

WA

•

To a

ddre

ss t

he

in

cre

asin

g g

lob

al im

pa

ct

of

AID

S o

n w

om

en

an

d g

irls

•

To h

elp

meet

a s

eri

es o

f a

mbitio

us

inte

rnatio

na

l targ

ets

•

To s

up

port

the

wid

er

glo

ba

l A

IDS

re

spo

nse

•

To im

pro

ve p

reve

ntion f

or

wom

en a

nd

gir

ls

•

To a

ddre

ss s

evere

so

cie

tal and leg

al in

eq

uitie

s w

hic

h c

om

po

un

d th

e im

pa

ct

of

HIV

and

AID

S o

n w

om

en a

nd g

irls

•

To p

revent

HIV

in

fect

ion a

mong

gir

ls a

nd y

ou

ng w

om

en

•

To r

edu

ce v

iole

nce

ag

ain

st

wom

en

•

To p

rote

ct

the p

rop

ert

y and

inh

erita

nce r

ights

of

wom

en a

nd g

irls

•

To e

nsure

equ

al a

cce

ss b

y w

om

en

an

d g

irls

to

care

an

d tre

atm

en

t •

To s

up

port

im

pro

ved c

om

munity-

ba

sed c

are

, w

ith a

sp

ecia

l fo

cus o

n w

om

en

an

d g

irls

•

To p

rom

ote

acce

ss

to n

ew

pre

ven

tion o

ption

s f

or

wom

en,

inclu

din

g m

icro

bic

ides

•

To s

up

port

on-g

oin

g e

ffort

s tow

ard

s u

niv

ers

al e

du

catio

n f

or

girls

GE

T 2

020

ww

w.w

ho.int/pbd/tra

chom

a/p

ress

rel.htm

•

Glo

ba

l elim

ination

of

blin

din

g tra

cho

ma b

y 202

0

•

To

im

ple

me

nt

the

SA

FE

str

ate

gy

con

sis

ting

of

Surg

ery

, A

ntib

iotic t

rea

tmen

t, p

rom

otio

n o

f F

acia

l cle

an

line

ss a

nd

in

itia

tio

n o

f E

nvi

ronm

enta

l cha

nge

s t

o r

edu

ce t

he tra

nsm

issi

on

of

trach

om

a

•

To

co

mb

ine

the

ab

ove

com

po

ne

nts

w

ith

m

edic

al,

beha

vio

ura

l a

nd

en

viro

nm

en

tal

str

ate

gie

s th

rou

gh th

e

targ

eting

of

com

mu

nitie

s

•

To i

nclu

de s

anitary

infr

astr

uctu

re a

nd s

erv

ices,

lifesty

le a

nd

hea

lth r

ela

ted b

eh

avio

ura

l aspe

cts

in a

imin

g a

t a s

usta

ina

ble

and

lon

g lastin

g r

ed

uctio

n o

r elim

inatio

n o

f tr

ach

om

a

GF

AT

M

ww

w.t

heglo

balfund.o

r

•

To f

ina

nce

a d

ram

atic turn

-aro

un

d in t

he fig

ht

aga

inst

AID

S, tu

berc

ulo

sis

an

d m

ala

ria

•

To a

ttra

ct, m

an

ag

e a

nd d

isburs

e a

dd

itio

nal

mon

ies w

ith l

ess

bu

reau

cra

cy

for

recip

ient

co

untr

ies,

allo

win

g m

ore

effe

ctiv

e

Mappin

g G

lobal H

ealth P

art

ners

hip

s

15

DF

ID H

ealth R

esourc

e C

entr

e

g/e

n/

use

of

don

or

resourc

es, an

d few

er

tran

sa

ctio

n c

osts

fo

r a

ll •

To d

ire

ct

fin

an

cia

l re

sourc

es

wh

ere

th

ey

are

nee

de

d m

ost

an

d e

nsu

re th

at th

ey

are

use

d e

ffe

ctively

GF

UN

C

•

to d

eve

lop p

ote

nt,

safe

, ora

lly a

ctive a

nd e

co

nom

ical n

ew

dru

gs

to tre

at A

fric

an t

ryp

ano

so

mia

sis

an

d leis

hm

an

iasi

s

•

To c

arr

y ou

t P

ha

se I

I C

linic

al T

rials

of

the

in

itia

l d

rug

(D

B2

89)

for

Afr

ica

n try

pa

no

som

iasi

s

•

To

syn

the

sis,

scr

ee

n

an

d

de

ve

lop

se

con

d

genera

tion

com

po

und

s

rela

ted

to

D

B2

89

for

the

tre

atm

ent

of

Afr

ica

n

tryp

ano

som

iasi

s

•

To s

ynth

esiz

e,

scr

ee

n a

nd

de

velo

p n

ove

l co

mp

ound

s f

or

the t

reatm

ent

of

leis

hm

an

iasis

. S

tud

ies

by

the c

onsort

ium

ha

ve

alre

ad

y show

n tha

t com

po

unds s

tru

ctura

lly r

ela

ted

to D

B28

9 a

re a

ctive,

both

in v

ivo a

nd in v

itro

, a

gain

st

leis

hm

an

iasis

Glo

bal

Buru

li’s

Ulc

er

Initi

ative

w

ww

.who.int/g

tb-

buru

li/in

itia

tive/in

dex.h

tml

•

To a

dvo

cate

for

Bu

ruli

ulc

er

as

a h

ealth a

nd d

evelo

pm

en

tal pro

ble

m

•

To s

ee

k p

art

ne

rsh

ip for

con

trol a

nd r

ese

arc

h

•

To c

o-o

rdin

ate

glo

ba

l con

tro

l an

d r

ese

arc

h e

ffort

s.

Glo

bal

Part

ners

hip

to

E

limin

ate

R

iver

Blin

dness

ww

w.w

orldba

nk.o

rg/a

fr/

gper/

part

ners

hip

s.ht

m

•

To e

limin

ate

Riv

erb

lindne

ss

as a

pu

blic

hea

lth

pro

ble

m in

all

of A

fric

a,

where

99

% o

f th

e w

orld

’s c

ase

s occur.

N

B T

he G

lob

al

Pa

rtners

hip

is a

n u

mbre

lla t

erm

fo

r th

e O

ncho

cerc

iasi

s C

on

trol

Pro

gra

m (

OC

P)

an

d t

he A

fric

an P

rogra

m f

or

Onch

ocerc

iasi

s C

ontr

ol (A

PO

C).

Th

e O

CP

ra

n f

rom

1974

-200

2 in 1

1 W

est

Afr

ica

n c

ou

ntr

ies.

It h

alte

d t

ransm

issio

n a

nd

virtu

ally

elim

inate

d R

ive

rblin

dn

ess t

hro

ug

hou

t p

art

icip

atin

g c

ou

ntr

ies,

tho

ug

h o

pera

tio

ns c

ontinue

in f

ive S

pe

cia

l In

terv

en

tio

n Z

one

s.

For

curr

ent

op

era

tion

s,

see

AP

OC

abo

ve.

GM

AI

•

To a

ctiva

te m

edia

org

an

iza

tion

s t

o r

ea

ch

the

worl

d’s

peop

le –

esp

ecia

lly y

outh

- w

ith info

rmatio

n a

bout

how

to p

reve

nt

and

tr

eat

HIV

and t

o h

elp

com

ba

t A

IDS

-re

late

d s

tigm

a a

nd

dis

crim

inatio

n

GM

P

ww

w.c

onra

d.o

rg/

•

To s

peed t

he d

evelo

pm

en

t an

d t

est

ing o

f m

icro

bic

ides,

topic

al

app

lication

s co

nta

inin

g c

om

pou

nd

s th

at

dis

ab

le o

r b

lock

age

nts

ca

usin

g s

exua

lly tra

nsm

itte

d infe

ctio

ns

(ST

Is)

•

To a

llow

sys

tem

atic s

cre

en

ing o

f ca

ndid

ate

lea

ds

and

para

llel

testin

g o

f ca

nd

ida

te m

icro

bic

ide

s in

hum

an t

ria

ls i

n o

rder

to

acce

lera

te le

ad-t

ime

fro

m labo

rato

ry t

o th

e m

ark

et

GO

AR

N

ww

w.w

ho.int/csr/

outb

reakne

twork

/en

/

•

To c

ontr

ibute

to

wa

rds

glo

ba

l he

alth s

ecu

rity

•

To c

om

ba

t th

e in

tern

atio

nal spre

ad o

f ou

tbre

aks

•

To e

nsu

re t

ha

t ap

pro

pria

te te

chnic

al a

ssis

tance r

ea

ches a

ffe

cted

sta

tes r

apid

ly

•

To c

ontr

ibute

to long

-term

epid

em

ic p

repa

red

ness a

nd

ca

pa

city

build

ing

GP

EI

ww

w.p

olio

era

dic

atio

n.

org

/

•

Th

e g

oa

l is

to h

ave

inte

rrup

ted t

ransm

issio

n o

f w

ild p

olio

virus b

y en

d-2

00

4 a

nd t

o c

ert

ify

the w

orl

d p

olio

-fre

e in 2

00

8

•

To

con

duct

eff

ective a

nd

hig

h q

ua

lity

su

pple

me

nta

ry im

mu

niz

ation

activiti

es,

inclu

din

g n

ation

al im

mu

nis

atio

n d

ays

and m

op-

up c

am

pa

ign

s t

o inte

rru

pt

wild

po

lioviru

s tra

nsm

issio

n

•

To d

evelo

p a

nd s

ust

ain

ce

rtifi

cation

sta

nd

ard

su

rve

illa

nce

an

d l

abo

rato

ry s

yste

ms

that

can r

apid

ly i

dentify

po

lio-i

nfe

cte

d

Mappin

g G

lobal H

ealth P

art

ners

hip

s

16

DF

ID H

ealth R

esourc

e C

entr

e

are

as

•

To e

nsure

la

bo

rato

ry c

onta

inm

en

t of w

ild p

olio

viru

s st

ock

s •

To d

eve

lop a

con

sensus s

trate

gy

to s

top p

olio

im

mu

nis

atio

n a

fte

r cert

ific

ation o

f e

radic

atio

n

•

To u

se

po

lio e

radic

atio

n t

o s

tren

gth

en a

nd e

xpan

d r

outine im

mun

isation s

erv

ice

s

Mappin

g G

lobal H

ealth P

art

ners

hip

s

17

DF

ID H

ealth R

esourc

e C

entr

e

GP

HW

w

ww

.glo

balh

and

washi

ng.o

rg

•

To r

edu

ce t

he

in

cid

ence

of

dia

rrho

ea

l dis

ea

se

s in

po

or

co

mm

unitie

s th

rou

gh p

ub

lic-p

riva

te p

art

ners

hip

s p

rom

oting

ha

nd

w

ashin

g w

ith s

oap

•

To im

ple

me

nt

larg

e s

ca

le h

and w

ashin

g inte

rve

ntion

s a

nd u

se le

sso

ns

to p

rom

ote

th

e a

ppro

ach

at

glo

bal le

ve

l •

Pro

gra

ms inclu

de p

rodu

cin

g t

each

er

less

on

pla

ns,

dis

trib

uting

ed

ucation

al po

ste

rs,

and

de

ve

lopin

g m

ass m

edia

cam

pa

ign

s

duri

ng in

fect

iou

s d

isea

se o

utb

rea

ks

GR

I w

ww

.glo

balreport

ing.o

rg/

•

To re

searc

h a

nd d

eve

lop

a st

and

ard

ize

d pro

toco

l fo

r co

mpa

nie

s to

pu

blic

ly re

po

rt in

form

ation o

n H

IV/A

IDS

p

olic

ies,

pra

ctic

es a

nd p

rogra

ms

GW

EP

w

ww

.cart

erc

ente

r.org

/healthpro

gra

ms/s

how

doc.a

sp?pro

gra

mID

=1&

subm

enu=

health

pr

ogra

ms

•

To a

cce

lera

te t

he e

radic

ation o

f g

uin

ea w

orm

dis

ea

se b

y th

e y

ear

20

05

•

To im

ple

me

nt eff

ect

ive

case

conta

inm

en

t m

easu

res in

all

en

de

mic

vill

age

s

•

To m

ain

tain

a co

mm

unity-

base

d surv

eill

an

ce sys

tem

w

ith m

onth

ly re

port

ing

of

case

s,

sup

erv

isio

n,

and in

teg

ratio

n o

f su

rve

illa

nce

for

oth

er

majo

r pre

ve

nta

ble

dis

ea

ses (

whe

re a

pp

ropri

ate

an

d f

ea

sib

le)

•

To t

arg

et

spe

cific

inte

rven

tion

s (

pro

vis

ion o

f sa

fe w

ate

r, h

ealth e

du

cation,

co

mm

un

ity

mo

bili

zation,

filter

dis

trib

utio

n,

and

tr

eatm

ent

of

sele

cte

d w

ate

r so

urc

es)

•

To m

ain

tain

g

lob

al

an

d n

atio

na

l dra

cu

ncu

liasis

d

ata

ba

ses fo

r m

on

itori

ng

of

the epid

em

iolo

gic

al

situ

atio

n a

nd m

ap all

end

em

ic v

illage

s

•

To s

usta

in a

dvo

cacy

for

era

dic

atio

n o

f th

e d

ise

ase

•

To c

ert

ify

dra

cun

culia

sis

era

dic

atio

n c

oun

try

by

cou

ntr

y w

orl

dw

ide

HA

CI

ww

w.h

opefo

rafr

icanch

ildre

n.o

rg/

•

To m

ob

ilize

a g

loba

l in

itia

tive

to a

ddre

ss

the n

ee

ds o

f A

fric

an c

hild

ren a

ffect

ed b

y H

IV/A

IDS

an

d t

o e

ng

ag

e,

stre

ngth

en

ca

pacitie

s, m

ob

ilize

an

d s

hare

eff

ective p

ractice

s a

mo

ng s

takeh

old

ers

at

all

leve

ls

•

To b

uild

aw

are

ne

ss a

nd r

educe th

e s

tig

ma

surr

ound

ing H

IV/A

IDS

•

To e

xte

nd

th

e life

of

the

pa

rent-

child

re

lation

ship

th

rou

gh p

reve

ntion a

nd t

reatm

en

t, in

clu

din

g n

utr

itio

n a

nd h

om

e b

ased

care

•

To p

rep

are

fa

mili

es

for

the

loss

of

a p

are

nt

thro

ugh

su

cce

ssio

n p

lan

nin

g a

s w

ell

as p

syc

ho

-so

cial and e

cono

mic

su

ppo

rt

•

To e

nsure

the c

hild

's f

utu

re b

y securin

g c

ontinu

ed a

cce

ss

to e

du

catio

n a

nd h

ea

lth c

are

follo

win

g t

he d

eath

of

on

e o

r both

pare

nts

HA

TC

•

Assis

t co

untr

ies i

n i

mp

lem

en

ting l

arg

e-s

cale

, in

tegra

ted c

are

, tr

ea

tme

nt, a

nd

pre

ven

tion

pro

gra

mm

es t

ha

t w

ill t

urn

the t

ide

on t

he A

IDS

ep

ide

mic

•

Pio

ne

eri

ng n

ew

ap

pro

ach

es

to t

he s

cale

-up o

f h

igh

qualit

y tr

eatm

ent

in t

he d

evelo

pin

g w

orld.

It i

s i

ntr

od

ucin

g t

ota

l q

ua

lity

mana

ge

ment

an

d c

olla

bo

rative learn

ing

mo

de

ls in

to t

he c

are

an

d tre

atm

ent

de

live

r sys

tem

s

Mappin

g G

lobal H

ealth P

art

ners

hip

s

18

DF

ID H

ealth R

esourc

e C

entr

e

HH

VI

ww

w.s

abin

.org

/hookw

orm

.htm

•

To d

evelo

p a

re

com

bin

ant

antig

en v

acci

ne t

o p

reve

nt

hum

an h

oo

kw

orm

in

fectio

n t

hat

will

be

nefit

the d

eve

lop

ing w

orld

co

untr

ies

HIN

w

ww

.healthin

tern

etw

ork

.org

/

•

To e

sta

blis

h k

ey

alli

an

ces in

the

are

as

of h

ealth in

form

atio

n, te

chn

olo

gy,

tra

inin

g,

con

ne

ctivity

an

d in

fra

stru

ctu

re b

uild

ing

•

To s

tre

ngth

en p

ub

lic h

ea

lth s

erv

ice

s u

sing

Inte

rne

t te

chn

olo

gie

s

•

To e

nha

nce com

mun

icatio

ns

with

in pu

blic

h

ea

lth co

mm

unity

thro

ugh

acce

ss

to m

ed

ical

and

scie

ntif

ic jo

urn

als

b

ein

g

ava

ilab

le o

n th

e In

tern

et to

me

dic

al scho

ols

and r

ese

arc

h in

stitu

tion

s in

develo

pin

g c

ountr

ies

•

To im

pro

ve g

lobal pu

blic

he

alth

by

facili

tating t

he f

low

of hea

lth

in

form

atio

n w

orl

dw

ide

•

To p

rovid

e a

nd

pro

mote

tra

inin

g,

info

rma

tio

n a

nd c

om

mun

icatio

ns

tech

no

log

y a

pplic

atio

ns for

pu

blic

hea

lth

HT

VN

w

ww

.hvtn

.org

/

•

To s

pe

ed

th

e d

eve

lopm

ent

of

an

eff

ective H

IV v

acc

ine

•

To

cond

uct

all

pha

se

s o

f clin

ica

l tr

ials

, fr

om

eva

luatin

g c

and

idate

va

cci

ne

s f

or

safe

ty a

nd

th

e a

bili

ty t

o s

tim

ula

te i

mm

un

e

respo

nse

s, to

te

stin

g v

acci

ne e

ffic

acy.

IAV

I w

ww

.iavi.org

•

To e

nsure

the d

eve

lop

men

t of safe

, eff

ective a

cce

ssi

ble

pre

ventive H

IV v

accin

es f

or

use

thro

ugh

out

the w

orl

d

•

Build

wo

rldw

ide

dem

an

d f

or

HIV

va

ccin

es t

hro

ug

h a

dvo

ca

cy

and

edu

cation b

y m

ob

ilizin

g s

upport

for

acce

lera

ted v

accin

e

develo

pm

en

t •

Ad

van

ce s

cie

ntific p

rogre

ss b

y su

pp

ort

ing p

rom

isin

g v

acci

ne

develo

pm

ent

part

ne

rsh

ips

an

d m

ovin

g t

he

m f

orw

ard

in

as f

ast

a tim

e p

eri

od a

s p

ossib

le a

s w

ell

as

identify

ing a

nd

fill

ing o

the

r sc

ientif

ic g

ap

s •

Foste

r a

n

en

viro

nm

en

t fo

r su

cce

ssfu

l va

ccin

e

develo

pm

ent

by

exp

an

din

g

pu

blic

-pri

vate

colla

bora

tio

n

and

cre

ating

in

centive

s for

private

se

cto

r in

vestm

ent

an

d p

art

icip

atio

n in

HIV

va

ccin

e d

eve

lop

ment

•

Assure

glo

ba

l acce

ss b

y cr

eatin

g t

he p

olic

ies

now

tha

t w

ill b

e n

ece

ssary

to

get

the v

accin

e t

o a

ll th

ose

who n

eed

it

IDR

I w

ww

.idri.o

rg/

•

To t

ran

sla

te ide

as to

pro

du

cts

fo

r th

e c

on

trol of d

isea

ses,

of th

e d

evelo

pin

g w

orld

•

To id

entify

earl

y sci

en

tific

leads for

va

ccin

es,

dia

gn

ostics

, or

thera

peutics

•

To d

eve

lop t

he

se le

ad

s in

to p

rodu

cts

that

can

ulti

mate

ly b

e p

rod

uced in t

he

co

untr

ies th

at n

ee

d t

he

m

IOW

H

ww

w.o

new

orldhealth.

org

•

To e

nsure

new

dru

g d

eve

lopm

en

t fo

r dis

ea

ses

tha

t aff

ect

peo

ple

in th

e d

eve

lopin

g w

orld

. •

To e

nlis

t th

e c

apab

ility

of

the d

eve

lop

ing w

orl

d t

o m

an

ufa

cture

new

dru

gs

follo

win

g r

eg

istr

atio

n,

there

by

co

ntr

ibutin

g t

o t

heir

affo

rda

bili

ty

•

To e

sta

blis

h a

dru

g d

eve

lopm

en

t tr

ain

ing f

ello

wsh

ip f

or

scie

ntists

fro

m t

he d

eve

lopin

g w

orld,

so t

hat

R&

D c

an e

ventu

ally

be

equ

itab

ly d

istr

ibu

ted a

rou

nd t

he

glo

be

•

To

im

pro

ve glo

ba

l h

ea

lth b

y d

eve

lop

ing n

ew

th

era

pie

s fo

r n

egle

cte

d dis

eases via

part

ne

rsh

ips

with in

tern

atio

na

l a

nd

Mappin

g G

lobal H

ealth P

art

ners

hip

s

19

DF

ID H

ealth R

esourc

e C

entr

e

govern

me

nt

ag

encie

s, t

he p

ha

rmace

utical in

du

str

y an

d a

cad

em

ia

IPA

AA

•

To

red

uce t

he

num

be

r of

new

HIV

infe

ctio

ns i

n A

fric

a,

pro

mote

care

for

tho

se w

ho

are

infe

cte

d w

ith

th

e v

iru

s a

nd

mo

bili

se

soci

ety

to s

top th

e a

dvan

ce o

f A

IDS

•

To a

ddre

ss s

ocia

l, e

con

om

ic a

nd c

ultura

l in

equ

alit

ies a

s w

ell

as i

nju

stic

es

whic

h a

re t

he r

oo

t ca

use

s o

f th

e e

pid

em

ic;

an

d

not

just

health issu

es

•

To c

ontr

ibu

te t

o g

lob

al

eff

ort

s t

o c

urt

ail

the s

pre

ad

of

HIV

in A

fric

a a

nd r

edu

ce i

ts i

mp

act

on

hu

ma

n,

so

cia

l and e

con

om

ic

develo

pm

en

t

•

To in

cre

ase

the r

esourc

es a

va

ilab

le t

o n

atio

nal g

ove

rnm

ents

and

com

mu

nitie

s t

o m

oun

t a

n a

de

qu

ate

re

spo

nse

to t

he A

IDS

epid

em

ic

•

To e

nsu

re t

hat

co

un

trie

s a

re l

inked

to

sub

-re

gio

na

l, r

eg

iona

l a

nd i

nte

rna

tiona

l re

sou

rce

s a

nd i

nitia

tive

s in

ord

er

to b

enefit

from

oth

er

inte

rnationa

l an

d r

egio

na

l investm

ents

in a

ddre

ssi

ng t

he e

pid

em

ic

•

To s

tep u

p p

reve

ntion

pro

gra

mm

es

IPM

w

ww

.ipm

-m

icro

bic

ides.

org

/

•

To i

ncre

ase

the

effic

ien

cy

of

the d

eve

lop

me

nt

an

d d

eliv

ery

of

a m

icro

bic

ide b

y e

xpa

nd

ing t

he b

read

th a

nd l

eve

l o

f pu

blic

and

pri

vate

secto

r fu

ndin

g

•

To id

entify

an

d fill

cri

tica

l gap

s in

researc

h &

de

ve

lop

men

t, a

ccess,

an

d a

dvo

cacy

•

To le

vera

ge

pa

rtn

ers

hip

s w

ith b

oth

new

an

d e

xisting

pu

blic

an

d p

riva

te p

laye

rs

•

To h

elp

to

rais

e a

ware

ne

ss o

f m

icro

bic

ide

s e

very

wh

ere

ITI

ww

w.t

rachom

a.o

rg/h

om

e.a

sp

•

ITI

is d

edic

ate

d t

o t

he e

limin

atio

n o

f b

lindin

g tra

chom

a

•

To t

arg

et

sup

port

fo

r e

xpa

nded

im

ple

me

nta

tion

of

the S

AF

E s

trate

gy

thro

ug

h:

Su

rgery

, A

ntibio

tics,

Face w

ashin

g,

an

d

En

viro

nm

enta

l cha

nge

•

To c

oo

rdin

ate

dis

trib

utio

n o

f P

fize

r's d

ona

tio

n o

f Z

ith

rom

ax for

tra

ch

om

a c

ontr

ol to

en

sure

its

ap

pro

pri

ate

use

•

To c

olla

bora

te w

ith

inte

rna

tiona

l ag

en

cies a

nd g

overn

me

nta

l an

d n

ongo

vern

men

tal a

gen

cie

s to

su

pp

ort

GE

T 2

02

0

JP

MW

•

To f

oste

r th

e d

iscovery

and

de

velo

pm

ent

of

new

an

tim

ala

ria

ls t

o r

ed

uce th

e m

ala

ria

bu

rde

n in e

nd

em

ic c

ou

ntr

ies

•

To t

est

over

10,0

00 c

om

po

und

s o

f div

ers

e c

he

mic

al

str

uct

ure

fro

m t

he c

hem

ica

l lib

rari

es

of

14

Ja

pan

ese p

harm

ace

utica

l co

mp

an

ies,

over

the

ne

xt f

ive y

ears

, fo

r an

timala

ria

l activ

ity

•

To r

egis

ter

at

lea

st

on

e a

ntim

ala

ria

l with

in t

he n

ext 1

0 y

ears

suitab

le f

or

the

tre

atm

en

t of

mala

ria in

en

dem

ic c

ou

ntr

ies

LA

PD

AP

•

To

de

velo

p "

LA

PD

AP

" (c

hlo

rpro

gu

anil-

da

pso

ne)

as a

n e

ffective o

ral

trea

tme

nt

for

un

co

mplic

ate

d m

ala

ria

, p

rim

ari

ly f

or

use

in

Su

b-S

ah

ara

n A

fric

a,

bu

t als

o in o

ther

regio

ns o

f th

e w

orld

wh

ere

it m

ay

be a

ppro

priate

•

Pha

se I

II tri

als

on L

AP

DA

P w

ere

con

du

cted

in

Gabo

n,

Ken

ya,

Ma

law

i, N

igeri

a a

nd

Ta

nzan

ia

LF

I •

To im

pro

ve th

e c

on

trol of L

assa f

ever

an

d e

ncou

rag

e t

he d

evelo

pm

en

t of, n

ew

an

d a

fford

ab

le inte

rve

ntion

s

•

To s

yste

ma

tica

lly a

ssess

the s

ocia

l and

econ

om

ic i

mpa

ct

of

Lassa

feve

r in

Sie

rra

Leon

e a

nd c

hara

cte

rize

th

e d

iffe

ren

t in

terv

en

tion

s a

va

ilable

in te

rms

of im

pa

ct, t

ime f

ram

e,

su

sta

ina

bili

ty a

nd t

he

ir r

ela

tive c

ost e

ffectiven

ess

•

To d

efine

th

e e

xte

nt o

f th

e d

isea

se b

urd

en a

nd

ris

k in q

ua

litative t

erm

s, b

ack

ed u

p w

ith th

e q

uantita

tive d

ata

where

it e

xis

ts

•

To

su

pp

ort

an

d b

uild

capa

city

at

the

curr

ent

tre

atm

ent

facili

ty S

ierr

a L

eo

ne

an

d d

eve

lop

th

e p

revention

re

spo

nse

at

the

co

mm

un

ity

level

Mappin

g G

lobal H

ealth P

art

ners

hip

s

20

DF

ID H

ealth R

esourc

e C

entr

e

•

To id

entify

the

mo

st

cost

eff

ect

ive

inte

rven

tio

ns for

the c

on

trol of th

e d

ise

ase

•

To id

entify

part

ners

fo

r d

eve

lopin

g n

ew

inte

rven

tion

s

Mappin

g G

lobal H

ealth P

art

ners

hip

s

21

DF

ID H

ealth R

esourc

e C

entr

e

MD

P 1

w

ww

.mectiz

an.o

rg/

•

To d

onate

Me

ctiz

an

for

on

chocerc

iasi

s w

orldw

ide t

o b

ring

the d

ise

ase u

nd

er

con

tro

l a

s a

pub

lic h

ealth p

roble

m,

an

d f

or

the

elim

ination

of

lym

ph

atic f

ilaria

sis

(L

F)

in A

fric

a w

here

onch

ocerc

iasis

and L

F c

o-e

xis

t •

To

serv

e a

s an in

dep

en

de

nt

org

an

ization t

o f

acili

tate

the

don

atio

n a

nd

de

livery

of

Me

ctizan t

o c

ountr

ies in A

fric

a a

nd

La

tin

Am

eri

ca

en

de

mic

for

on

cho

cerc

iasi

s,

an

d t

o c

oun

trie

s in A

fric

a w

here

onch

oce

rcia

sis

and

lym

phatic

fila

riasis

co-e

xis

t

MD

P 2

w

ww

.mdp.m

rc.a

c.u

k/

•

To d

ete

rmin

e t

he s

cie

ntific m

echan

ism

s u

nde

rlyi

ng

the

activity

of

mic

rob

icid

al ag

en

ts

•

To c

on

du

ct

pre

-clin

ica

l eva

lua

tion

of

pote

ntia

l m

icro

bic

ides

•

To u

nde

rta

ke P

hase I

and P

ha

se I

I st

ud

ies

of

ne

w p

rod

ucts

and

com

bin

ation

s in h

ea

lthy

fem

ale

vo

lunte

ers

and w

om

en

with

H

IV

•

To c

om

pare

diff

ere

nt

pro

duct

s a

nd f

orm

ula

tion

s i

n h

ea

lth

y fe

male

vo

lunte

ers

in

term

s o

f th

eir

cerv

ico-v

agin

al

dis

trib

ution

and

rete

ntio

n b

y im

ag

ing

•

To u

nd

ert

ake f

ea

sib

ility

stu

die

s a

nd

Ph

ase II

mic

rob

icid

e tri

als

as a

pre

lud

e to

Ph

ase

III

stu

die

s

•

To u

nd

ert

ake in A

fric

a a

multin

atio

nal P

ha

se III

, ra

ndo

mis

ed,

do

ub

le b

lind

, pla

ceb

o c

ontr

olle

d tri

al o

f ca

ndid

ate

com

poun

ds

•

To a

ddre

ss

issue

s r

ais

ed b

y th

e a

vaila

bili

ty o

f an e

ffect

ive

mic

robic

ide

in r

ela

tio

n t

o t

heir w

idesp

rea

d i

ntr

odu

ctio

n t

hro

ugh

co

llabora

tio

ns

with b

eha

vio

ura

l scie

ntist

s, h

ea

lth e

co

nom

ists

an

d m

ath

em

atica

l mod

elle

rs

MI

ww

w.m

icro

nutr

ient.

or

g

•

To e

nd

mic

ronutr

ient

ma

lnu

triti

on thro

ug

ho

ut

the

worl

d.

•

To in

crea

se

acc

ess t

o e

sse

ntia

l m

icro

nu

trie

nts

•

To s

tim

ula

te a

nd s

upp

ort

natio

na

l a

ctio

ns to

elim

inate

mic

ronu

trie

nt m

aln

utr

itio

n

•

To intr

odu

ce a

nd

expa

nd

fo

od f

ort

ifica

tion a

nd d

ieta

ry s

upp

lem

enta

tion

pro

gra

ms

•

To a

dva

nce

glo

ba

l a

bili

ty t

o a

ddre

ss iro

n d

eficie

ncy

an

em

ia,

an

d t

o e

ncoura

ge in

tern

ation

al d

evelo

pm

en

t eff

ort

s t

o a

llevi

ate

th

e b

urd

en o

f m

icro

nutr

ien

t m

aln

utr

itio

n.

MIM

w

ww

.mim

.su.s

e/

•

To s

tren

gth

en a

nd s

usta

in,

thro

ug

h c

olla

bo

rative

re

sea

rch

an

d t

rain

ing,

the c

ap

ab

ility

of

ma

lari

a e

nde

mic

cou

ntr

ies in

Afr

ica

to

carr

y o

ut

researc

h r

equ

ired t

o d

eve

lop

an

d im

pro

ve t

oo

ls f

or

ma

lari

a c

on

tro

l •

To r

ais

e in

tern

ation

al pub

lic a

ware

ne

ss

of th

e p

roble

m o

f m

ala

ria

•

To p

rom

ote

glo

ba

l com

mun

ica

tion

an

d c

o-o

pera

tio

n in m

ala

ria

re

sea

rch

and tra

inin

g

•

To e

nsure

re

searc

h fin

din

gs a

re a

pp

lied t

o m

ala

ria t

reatm

ent

and c

on

trol.

MM

V

ww

w.m

mv.o

rg/p

ages/

page_m

ain

.htm

•

To b

rin

g p

ub

lic,

pri

vate

an

d p

hila

nth

ropic

sect

or

part

ners

to

geth

er

to f

und

and m

ana

ge t

he d

isco

very

, d

eve

lop

men

t and

re

gis

tration o

f n

ew

me

dic

ine

s fo

r th

e tre

atm

en

t an

d p

reve

ntion

of

ma

laria in d

ise

ase

-en

de

mic

cou

ntr

ies

•

To

b

uild

a p

ipelin

e o

f th

e

be

st

po

tentia

l antim

ala

rial

pro

jects

a

vaila

ble

in

th

e g

lob

al

researc

h

com

mu

nity

thro

ug

h

a

com

petitive

pro

posal

pro

cess a

nd to

m

anag

e th

e p

ort

folio

to

m

axim

ize

th

e re

su

lts fo

r th

e b

en

efit

of

mala

ria-e

nde

mic

co

untr

ies.

A su

cce

ssfu

l pip

elin

e w

ill g

en

era

te at

lea

st

one

n

ew

te

chn

ica

lly a

ppro

pria

te,

co

st-e

ffe

ctiv

e,

acc

essib

le and

affo

rda

ble

an

tim

ala

ria

l dru

g e

very

fiv

e y

ears

MN

T

•

Th

e g

lobal

elim

ina

tion

of

mate

rna

l and

ne

ona

tal

teta

nu

s a

s a

pub

lic h

ea

lth p

rob

lem

fo

r w

om

en

an

d n

ew

born

s b

y th

e y

ear

200

5

•

Rou

tine

im

mun

izatio

n o

f pre

gna

nt w

om

en

Mappin

g G

lobal H

ealth P

art

ners

hip

s

22

DF

ID H

ealth R

esourc

e C

entr

e

•

Sup

ple

me

nta

l T

T (

teta

nu

s to

xoid

) im

mun

ization t

o a

ll w

om

en

of

child

beari

ng a

ge (

15-4

5)

in h

igh-r

isk d

istr

icts

•

Pro

mo

tin

g h

ygie

nic

birth

ing

pra

ctice

s

MT

CT

-Plu

s

ww

w.m

tctp

lus.o

rg

•

To

pro

vid

e

ba

sic

ca

re

for

pre

ventio

n

and/o

r tr

ea

tment

of

HIV

-rela

ted

op

po

rtunis

tic

infe

ction

s

and

tr

eatm

ent

with

antire

tro

vira

l dru

gs

•

To

work

thro

ugh

exis

tin

g m

oth

er-

to-c

hild

tra

nsm

issio

n (

MT

CT

) p

rogra

ms

that

use

we

ll-e

sta

blis

hed

tre

atm

en

ts,

inclu

din

g

sing

le d

ose

s of n

evira

pin

e a

dm

inis

tere

d t

o t

he p

regna

nt

mo

ther

and infa

nt

•

To p

rovid

e t

ech

nic

al a

ssis

tance, a

dd

itio

na

l sta

ff tra

inin

g if re

qu

ired

, overs

igh

t, a

nd

dru

gs inclu

din

g a

ntire

tro

vir

al t

hera

py

MV

I

ww

w.m

ala

riavacci

ne.

org

/

•

To a

cce

lera

te t

he d

evelo

pm

en

t of

mala

ria v

acci

ne

s a

nd e

nsure

th

eir

ava

ilab

ility

and a

cce

ssi

bili

ty in th

e d

evelo

pin

g w

orl

d

•

To a

sse

ss

the m

ost pro

mis

ing m

ala

ria

va

ccin

e c

an

did

ate

s

•

To a

dvan

ce

th

e c

reation o

f com

bin

ation

an

d m

ulti-va

lent vaccin

es

•

To im

pro

ve th

e in

ve

stm

ent

environ

men

t fo

r m

ala

ria

va

ccin

e d

eve

lopm

ent a

nd d

eliv

ery

MV

P

ww

w.m

enin

gvax.

org

/

•

To e

limin

ate

epid

em

ic m

en

ingitis

as a

p

ub

lic h

ealth

pro

ble

m in

su

b-S

ah

ara

n A

fric

a th

rough

th

e de

ve

lopm

en

t, te

stin

g

licen

sure

, a

nd w

ide

spre

ad u

se o

f co

nju

gate

men

ingo

cocca

l vaccin

es

•

To d

eve

lop m

enin

go

cocca

l co

nju

gate

va

ccin

es

that

are

appro

pria

te f

or

use

in A

fric

a

•

To c

reate

path

wa

ys f

or

the

lic

en

sure

of

va

ccin

es

•

To a

ssure

pro

du

ctio

n in

suff

icie

nt

volu

me a

t a p

rice

th

at fa

cili

tate

s w

ide u

se in

Afr

ica

•

To m

onito

r th

e e

ffe

ctiv

en

ess

and s

afe

ty o

f th

e v

acci

ne

s in

contr

olle

d c

linic

al tr

ials

•

To in

vestig

ate

inn

ova

tive w

ays

to

fin

an

ce t

he

pro

cure

men

t of

va

ccin

es t

hro

ugh lo

ca

l, co

untr

y, a

nd

oth

er

glo

bal pro

gra

ms

•

To intr

odu

ce t

he v

acci

ne

s t

hro

ug

h m

ass

and

ro

utin

e im

mu

niz

ation

in s

yne

rgy

with o

ther

pu

blic

he

alth p

rogra

ms

NetM

ark

PLU

S

ww

w.n

etm

ark

afr

ica.o

rg/

•

To r

ed

uce

the

im

pa

ct o

f m

ala

ria i

n s

ub-S

ah

ara

n A

fric

a t

hro

ugh t

he i

ncre

ased

use

an

d s

ust

ain

ab

le s

up

ply

of

insecticid

e

treate

d m

osq

uito

ne

ts (

ITN

s),

an

d insectici

de

tre

atm

en

ts k

its f

or

ne

ts

•

To s

tren

gth

en a

nd s

usta

in,

thro

ug

h c

olla

bo

rative

re

sea

rch

an

d t

rain

ing,

the c

ap

ab

ility

of

ma

lari

a e

nde

mic

cou

ntr

ies in

Afr

ica

to

carr

y o

ut

researc

h r

equ

ired t

o d

eve

lop

an

d im

pro

ve t

oo

ls f

or

ma

lari

a c

on

tro

l. •

To r

ais

e in

tern

ation

al pub

lic a

ware

ne

ss

of th

e p

roble

m o

f m

ala

ria

•

To p

rom

ote

glo

ba

l com

mun

ica

tion

an

d c

o-o

pera

tio

n in m

ala

ria

re

sea

rch

and tra

inin

g

•

To e

nsure

re

searc

h fin

din

gs a

re a

pp

lied t

o m

ala

ria t

reatm

ent

and c

on

trol

PA

RT

NE

RS

w

ww

.taskfo

rce.o

rg/tbh

om

e.h

tml

•

Dem

onst

rate

th

e s

ucc

ess

of

TB

contr

ol p

rog

ram

s t

hat

com

bin

e D

OT

S w

ith c

on

trol of

MD

R-T

B in

Peru

and

Tom

sk a

nd t

ake

this

inte

gra

ted T

B c

ontr

ol p

rogra

m t

o s

cale

in

Peru

•

Define a

nd

esta

blis

h t

he

ne

cessa

ry infr

astr

uct

ure

in P

eru

to s

ust

ain

a s

ucc

essfu

l in

tegra

ted p

rogra

m a

fter

the

pro

ject

end

s;

define t

he p

ara

llel in

fra

str

uct

ure

tha

t w

ill b

e r

equ

ired t

o e

xpa

nd a

nd s

usta

in t

he

pro

gra

m in T

om

sk a

fter

the p

roje

ct e

nd

s •

Art

icu

late

th

e c

om

pone

nts

of

a r

eplic

ab

le,

ge

neri

c m

ode

l, d

raw

ing o

n t

he l

esso

ns f

rom

Peru

and

Russia

, fo

r in

teg

rate

d

pro

gra

ms t

hat

cou

ld b

e r

ep

lica

ted

in o

ther

hig

h-b

urd

en

cou

ntr

ies,

an

d p

rovid

e a

meth

od

olo

gy

for

do

ing s

o

•

Pro

vid

e str

ate

gie

s a

nd

a d

em

onstr

atio

n pla

tform

to

st

ren

gth

en th

e g

loba

l T

B co

ntr

ol

eff

ort

th

rou

gh le

sson

s fr

om

th

e

Mappin

g G

lobal H

ealth P

art

ners

hip

s

23

DF

ID H

ealth R

esourc

e C

entr

e

PA

RT

NE

RS

pro

ject

PD

VI

ww

w.p

dvi.org

/

•

To ra

ise a

ware

ne

ss

an

d w

ork

with public

an

d p

rivate

part

ne

rs in

th

e N

ort

h and th

e S

outh

in

ord

er

to accele

rate

the

develo

pm

en

t an

d i

ntr

od

uctio

n o

f a

de

ng

ue v

accin

e t

hat

is a

ppro

pri

ate

, safe

an

d a

ccessi

ble

to

po

or

ch

ildre

n i

n e

nde

mic

co

untr

ies

•

Con

duct

po

licy

stu

die

s t

o b

ett

er

unde

rsta

nd

nation

al p

rioritie

s o

n d

eng

ue

•

Coo

rdin

ate

cou

ntr

y surv

eys

nee

ded t

o b

ett

er

define

th

e b

urd

en o

f de

ngu

e illn

ess

•

Com

mis

sio

n m

ulti-dis

ciplin

ary

ana

lyse

s o

n t

he i

mpa

ct

of

den

gue

to b

ett

er

defin

e s

ocia

l a

nd e

cono

mic

co

sts

and

ma

rke

t pote

ntials

for

ped

iatr

ic d

en

gu

e v

acci

ne

s •

Pre

pa

re a

nd l

aun

ch a

scie

ntific b

lue

print

ch

art

ing

th

e c

halle

nge

s (

4 s

train

s,

safe

ty)

and o

pp

ort

un

itie

s (

bio

tech

nolo

gy,

new

va

ccin

e a

ppro

ach

es)

that

mu

st b

e m

et to

achie

ve a

safe

, eff

ect

ive

an

d a

fford

able

va

ccin

e

•

Sup

port

R&

D (

pha

se 3

fie

ld s

ite

s, s

afe

ty,

new

va

ccin

es)

and e

nh

an

ce d

evelo

pin

g c

ou

ntr

y scie

nce c

apa

city

•

Work

and pla

n ahe

ad w

ith

m

an

y sta

keh

old

ers

a

nd

org

aniz

atio

ns to

a

ccele

rate

th

e in

trod

uctio

n o

f a p

edia

tric

den

gu

e

vacc

ine in

en

de

mic

co

untr

ies

Pneum

oA

DIP

w

ww

.pre

ventp

neum

o.

org

•

Acce

lera

te t

he e

valu

atio

n o

f, a

nd a

ccess

to, n

ew

life

savin

g p

ne

um

ococca

l va

ccin

es f

or

the

world

’s p

oore

st c

hild

ren

•

Est

ab

lish

the

valu

e o

f va

ccin

atio

n b

y d

em

on

str

ating

the

burd

en o

f m

en

ingitis

and p

neum

on

ia c

au

se

d b

y p

neu

mo

co

cca

l bacte

ria

an

d d

em

on

stra

te t

he v

alu

e o

f pre

ve

nting it th

rou

gh

vacci

na

tion

•

Com

mun

icate

kn

ow

led

ge a

bou

t b

urd

en

of

dis

ease a

nd t

he v

alu

e o

f va

cci

na

tio

n b

y a

ssu

rin

g t

hat

the

re

sea

rch

ed b

ase

d

evid

ence is c

om

mu

nic

ate

d e

ffe

ctive

ly t

o k

ey

de

cisio

n m

akers

th

rou

gh a

ppro

priate

an

d e

ffe

ctive

co

mm

unic

ation c

hann

els

•

Deliv

er

the

valu

e o

f th

e v

acc

ine b

y a

ssuri

ng t

hat

there

is

a p

red

icta

ble

su

pply

of

qua

lity

vaccin

e t

o a

n a

ffo

rdab

le p

rice

and

an a

de

quate

sys

tem

to d

eliv

er

it t

o t

he c

hild

ren

wh

o n

eed it

RB

M

ww

w.r

bm

.who.int/part

ners

hip

/

•

To in

crea

se

glo

ba

l polit

ical co

mm

itm

ent to

ta

ckle

ma

lari

a m

ore

effe

ctive

ly th

roug

h c

oord

inate

d a

ction

•

To a

ssi

st

the h

ea

lth s

ect

or

to f

ocu

s re

so

urc

es o

n h

igh

dis

ea

se b

urd

en

s su

ch a

s m

ala

ria a

nd c

ost-

eff

ect

ive i

nte

rve

ntion

packa

ge

•

To in

crea

se

the

com

mitm

ent, a

mon

g th

e r

ese

arc

h c

om

mu

nity

and p

rivate

secto

r •

To d

isco

ver

new

pro

du

cts

and c

ost eff

ect

ive

co

ntr

ol to

ols

SC

I w

ww

.schis

to.o

rg/

•

To e

ncoura

ge d

eve

lop

men

t of a s

ust

ain

ab

le s

chis

toso

mia

sis

co

ntr

ol p

rogra

mm

e in

sub S

ah

ara

n A

fric

a

•

In t

he s

ele

cte

d c

ou

ntr

ies:

(1)

to r

each a

t le

ast

75

% o

f sch

oo

l-a

ge

ch

ildre

n a

nd o

ther

hig

h-r

isk g

roup

s w

ith c

hem

oth

era

py

- pra

ziqu

ante

l an

d a

lben

da

zole

; (2

) re

du

ce s

chis

toso

mia

sis

-re

late

d m

orb

idity

in h

igh r

isk g

roups;

(3)

red

uce

pre

vale

nce a

nd

in

tensity

of

sch

isto

som

iasi

s in

fectio

ns;

(4)

red

uce

bu

rden

s d

ue t

o in

testin

al he

lmin

ths in

the t

arg

ete

d p

op

ula

tions

•

Cre

ate

a d

em

and f

or

susta

ined s

chis

tosom

iasi

s c

ontr

ol

•

To p

rom

ote

acce

ss

to a

nth

elm

inth

ic d

rug

s a

nd g

oo

d c

ase

ma

nag

em

en

t in

the

re

gula

r h

ea

lth s

yste

m

SF

w

ww

.secure

thefu

ture

.

•

To p

revent

HIV

/AID

S a

nd

Sexu

ally

Tra

nsm

itte

d I

nfe

ctio

ns

•

To

redu

ce

th

e i

mp

act

of

HIV

/AID

S (

in S

outh

Afr

ica

, B

ots

wana

, N

am

ibia

, Le

soth

o,

Sw

azi

lan

d,

Sen

ega

l, C

ote

d'Iv

oire

, M

ali

and

Burk

ina F

aso

) o

n ind

ivid

ua

ls b

y e

mp

ow

eri

ng infe

cted a

nd a

ffe

cte

d w

om

en

an

d c

hild

ren

Mappin

g G

lobal H

ealth P

art

ners

hip

s

24

DF

ID H

ealth R

esourc

e C

entr

e

com

/ •

To e

xp

an

d a

cce

ss t

o tre

atm

en

t in

a n

um

ber

of

wa

ys

•

To

pro

vide

gra

nts

for

me

dic

al

rese

arc

h a

nd

com

mun

ity

ou

trea

ch

an

d e

du

cation

. It a

lso e

ncoura

ge

s a

nd

fu

nds c

apa

city-

build

ing

ed

uca

tion

al p

rogra

ms

in m

ed

icin

e,

hea

lth

care

and

pu

blic

hea

lth

SIG

N

ww

w.w

ho.int/in

ject

ion

_safe

ty/e

n/

•

Cre

ate

and m

ain

tain

a c

om

mon s

trate

gic

fra

me

work

•

Pro

mo

te e

xch

ang

e o

f id

ea

s a

nd info

rmatio

n to

en

cou

rage

re

sea

rch

on inn

ova

tive

, co

st-e

ffect

ive

ness s

olu

tion

s

•

Coo

rdin

ate

advocacy

and c

om

mun

ica

tio

n s

trate

gie

s.

Ste

p F

orw

ard

w

ww

.ste

pfo

rward

forc

hild

ren.o

rg/h

om

e.h

tm

•

To

im

pro

ve t

he

liv

es o

f orp

han

s a

nd v

uln

era

ble

ch

ildre

n a

ffe

cte

d b

y th

e A

IDS

pand

em

ic,

to i

ncre

ase

the

ir c

ha

nce

s o

f no

t ju

st s

urv

ivin

g th

e im

pa

ct

of

AID

S, b

ut of

be

com

ing

pro

ductive m

em

bers

of th

eir s

ocie

tie

s •

Imp

rove lo

cal he

alth s

erv

ices

and

infr

ast

ructu

re

•

Incr

ease

volu

nta

ry H

IV c

ou

nse

ling a

nd t

est

ing s

erv

ice

s •

Str

en

gth

en p

rim

ary

and

se

con

dary

ed

ucation p

rog

ram

s

•

Addre

ss b

asic

com

mu

nity

needs

such

as c

lean

, sa

fe w

ate

r, a

nd

help

ing p

eop

le t

o g

en

era

te n

ee

ded in

com

e

Sto

p

TB

P

art

ners

hip

w

ww

.sto

ptb

.org

/

•

En

sure

tha

t every

TB

patie

nt ha

s acce

ss

to T

B tre

atm

en

t a

nd

cure

•

Sto

p T

ran

smis

sion

of

TB

•

Pro

tect

vu

lnera

ble

po

pu

lations fro

m T

B

•

Red

uce

the s

ocia

l an

d e

co

nom

ic t

oll

tha

t T

B e

xert

s o

n f

am

ilie

s,

com

mu

nitie

s, a

nd

nation

s

•

Sto

p T

B p

riori

tie

s a

re t

o e

xpa

nd

, a

da

pt,

an

d i

mpro

ve s

trate

gie

s t

o c

ontr

ol a

nd e

limin

ate

TB

in

supp

ort

of

the W

orld H

ealth

Asse

mb

ly T

arg

ets

set

by

2005

(7

0%

Ca

se-d

ete

ction

an

d 8

5%

Cu

re-r

ate

s),

an

d th

e M

ille

nniu

m D

evelo

pm

en

t G

oals

TR

OP

IVA

L

ww

w.t

ropiv

al.o

rg/inde

x.php

•

To

coord

inate

R&

D p

roje

cts

con

du

cte

d b

etw

een

pu

blic

lab

ora

tori

es a

nd p

harm

ace

utica

l co

mp

an

ies a

s w

ell

as t

o p

rop

ose

treatm

ents

ada

pte

d t

o p

op

ula

tio

ns

livin

g in p

oo

r con

ditio

ns

•

To b

rin

g t

og

eth

er

rese

arc

hers

, in

du

str

ialis

ts,

spon

sors

an

d i

nte

rnation

al

org

an

izatio

ns

aro

und p

ote

ntial

pro

jects

that

wou

ld

ultim

ate

ly p

rovid

e the

rig

ht to

tre

atm

en

t to

tho

se p

op

ula

tion

s m

ost

in n

eed

•

To id

en

tify

pre

-de

velo

pm

ent

pro

ject

s an

d new

fo

rmula

tio

n ada

pte

d to

de

ve

lop

ing co

untr

ies a

s w

ell

as seek po

ten

tial

spo

nsors

VD

P

ww

w.p

mtc

tdonations.

org

/en/w

elc

om

e/

•

To p

revent

mo

the

r-to

-child

-tra

nsm

issi

on

(M

TC

T)

of H

IV-1

•

To p

rovid

e V

iram

un

e fr

ee

of

ch

arg

e fo

r a

p

eri

od o

f five

ye

ars

to

de

velo

pin

g cou

ntr

ies

in th

e conte

xt

of

a fe

asib

le,

sust

ain

able

, te

chn

ica

lly a

nd

eth

ically

app

ropri

ate

MT

CT

pre

ven

tion

pro

gra

mm

e.

VF

w

ww

.vacc

inefu

nd.o

rg/

•

To m

obili

ze r

eso

urc

es f

or,

ch

am

pio

n,

mo

nito

r th

e r

esu

lts

of, a

nd

he

lp s

usta

in G

AV

I

•

To m

obili

ze r

eso

urc

es t

o a

chie

ve im

mun

ization

suff

icie

ncy

and s

ust

ain

ab

ility

•

To a

ch

ieve r

eco

gnitio

n o

f a

nd s

up

port

fo

r th

e V

F m

issio

n s

o a

s to

maxim

ize th

e v

alu

e o

f its

bra

nd

•

To m

anag

e th

e V

F f

or

eff

icie

ncy

and a

cco

unta

bili

ty f

or

resu

lts

•

To e

nsure

with G

AV

I p

art

ners

th

at a

secure

sup

ply

of

all

rele

vant

va

cci

nes a

re a

cce

ssib

le t

o a

ll ta

rge

t coun

trie

s

•

Pro

vid

es

cou

ntr

ies

with

resourc

es t

o s

tren

gth

en r

outin

e i

mm

un

izatio

n s

erv

ice

s;

pa

ys f

or

va

ccin

es a

ga

inst

hepa

titis

B,

Hib

Mappin

g G

lobal H

ealth P

art

ners

hip

s

25

DF

ID H

ealth R

esourc

e C

entr

e

dis

ea

se a

nd

ye

llow

fe

ver,

and s

afe

in

jection m

ate

ria

ls

Mappin

g G

lobal H

ealth P

art

ners

hip

s

26

DF

ID H

ealth R

esourc

e C

entr

e

Vis

ion

2020

http://w

ww

.who.int/pb

d

•

To

elim

ina

te b

y th

e y

ear

20

20 t

he

ma

in c

auses o

f b

lind

ne

ss in

ord

er

to g

ive a

ll p

eop

le in

th

e w

orld,

pa

rtic

ula

rly

the

mill

ion

s

nee

dle

ssly

blin

d,

the

Rig

ht to

Sig

ht

•

To in

crea

se

aw

are

ne

ss

of

blin

dn

ess

as a

majo

r pu

blic

hea

lth issu

e

•

To c

on

tro

l th

e m

ajo

r avoid

able

ca

uses o

f b

lind

ne

ss

•

To m

ake a

vaila

ble

ap

pro

pri

ate

techno

log

y, infr

ast

ructu

res a

nd h

um

an r

eso

urc

es.

•

To

giv

e s

up

port

to N

ation

al co

mm

itte

es

and/o

r pro

gra

mm

es f

or

the p

reve

ntio

n o

f b

lindne

ss,

tow

ard

s a

chie

vin

g V

isio

n 2

020

goa

ls

VIT

A

•

To im

pro

ve th

e n

utr

ient

con

tent

of sta

ple

foo

ds t

hro

ugh

food

fort

ific

atio

n

•

To

rea

ch im

ple

me

nta

tio

n o

f nation

al sca

le,

hig

h c

ove

rage

vitam

in A

su

pp

lem

en

tation p

rogra

ms f

or

ch

ildre

n u

nder

five in

the

poo

rest a

nd

ha

rde

st

to r

each r

em

ote

are

as

•

To

en

sure

su

sta

inab

ility

of

VA

pro

gra

ms

by

main

stre

am

ing

pro

gra

ms

with

in

the

po

licie

s,

fundin

g

me

cha

nis

ms

an

d

stra

teg

ies

for

cou

ntr

y M

inis

trie

s o

f H

ea

lth

•

To d

eve

lop a

ltern

ative m

ech

anis

ms f

or

VA

supp

lem

en

t d

istr

ibutio

n d

urin

g p

ha

se o

ut

of

Natio

na

l Im

mu

niz

ation

Da

ys t

o

ensure

contin

uin

g h

igh

cove

rage

of

child

ren 6

-59 m

on

ths

•

To b

uild

an

d s

tre

ng

the

n p

rogra

ms for

impro

ved

de

livery

of

po

st-

part

um

vitam

in A

sup

ple

me

nts

•

To m

on

itor

the gro

wth

of

oth

er

pu

blic

h

ea

lth in

terv

ention

s such

as m

ea

sle

s va

ccin

atio

ns,

w

hils

t d

eliv

ering

vitam

in A

su

pple

me

nts

.

VV

M

ww

w.w

ho.int/vaccin

es

.acce

ss/v

acm

an/v

vm

/vvm

main

page.h

tm

•

To im

pro

ve q

ualit

y co

ntr

ol

duri

ng im

mu

nis

atio

n pro

gra

mm

es u

sin

g la

be

ls w

here

by

he

alth

wo

rke

rs c

an d

ete

rmin

e he

at

exp

osure

and

de

gra

datio

n o

f th

e v

accin

e

•

To im

pro

ve th

e m

ana

ge

me

nt

of

va

ccin

e a

nd r

ed

uce

wast

age

•

To d

ete

rmin

e v

accin

e s

afe

ty o

r w

heth

er

it s

hou

ld b

e d

iscard

ed

WP

ES

S

•

To

coord

inate

a

new

part

ne

rsh

ip fo

r th

e

surv

eill

an

ce,

co

ntr

ol, an

d tr

eatm

ent

of

sle

epin

g

sic

kne

ss

inte

gra

ting

sup

ply

agre

em

ents

, dis

ease m

ana

gem

ent,

an

d r

ese

arc

h

•

Ad

voca

cy

an

d a

ware

ne

ss:

resc

uin

g t

he d

isea

se fro

m o

bliv

ion

an

d in

cre

asi

ng

the v

isib

ility

of eff

ort

s.

•

Part

ners

hip

: ra

llyin

g p

art

ne

rs to s

upport

an e

limin

atio

n p

rog

ram

me

•

Sup

port

: st

ren

gth

en

ing t

he o

rga

niz

ation a

nd

im

ple

me

nta

tion o

f contr

ol a

ctivitie

s in

co

untr

ies

•

Coo

rdin

atio

n a

mu

ltip

le c

om

pan

y don

ation p

rogra

mm

e

•

Researc

h:

encoura

gin

g r

esearc

h in

stitu

tes

to f

un

d a

nd

imp

lem

en

t re

searc

h o

n d

rugs,

dia

gn

osis

an

d a

pplie

d r

ese

arc

h

•

Info

rmatio

n m

ana

gem

ent

and d

isse

min

ation

: exch

ang

ing

info

rmatio

n a

nd

pro

vid

ing t

rain

ing t

o t

ho

se i

nvo

lve

d i

n s

lee

pin

g

sickne

ss a

ctiv

itie

s

Sourc

e:

upd

ate

d f

rom

Buse

K.,

20

04. G

loba

l H

ealth P

art

ners

hip

s:

Map

pin

g a

shifting t

err

ain

. Lon

don

: D

FID

Health R

eso

urc

e C

en

tre

.



APPENDIX B: GLOBAL HEALTH PARTNERSHIPS – MAPPING BY COUNTRY EXERCISE Purpose To provide a global picture of where Global Health Partnerships provide support on a country by country basis, and with an overview of key country characteristics that might effect GHP support. Methodology The mapping exercise looked at a number of variables, which included:

• Global Health Partnerships • Country GDP per capita • Prevalence or cases of specific diseases of interest to target GHPs • Demographic characteristics • Poverty characteristics • Political characteristics • Health system characteristics, in terms of levels of financing.

These were then analysed by converting the table into a spreadsheet and sorting the data, using the number of GHPs as the independent variable, and all other factors as dependent variables. Full information was gathered for only a selection of countries in each region, focusing on those countries of greatest interest to DFID, as well as those with the largest number of GHPs providing support. Findings As far as the type of government is concerned, as measured on a scale of –10 (authoritarian) to +10 (fully democratic), there is no apparent correlation between the number and type of GHPs operating when looked at by type of government As far as public spending on health is concerned, there is no correlation between the percentage of spending on the health sector coming from the public purse and the number or type of GHPs operating in a country. There is a moderate correlation between the prevalence rate or case number of a disease and the presence of the relevant GHP, as would be expected. However, it is impossible to state whether GFATM is providing appropriate levels of funding for each of its three target diseases in each country where it is present, based on the epidemiology of the disease in that country, without looking at GFATM support on a country by country basis. There would appear to be a correlation between the per capita GDP and the number of GHPs operating in a country, though this is inconsistent. The strongest correlation is between the what region the country is part of and the number of GHPs operating in that country, with Africa having consistently the largest number of GHPs per country, followed by Asia (East, Southeast and Central). Eastern and Central European countries have the lowest number of GHPs.

Mappin

g G

lobal H

ealth P

art

ners

hip

s

28

DF

ID H

ealth R

esourc

e C

entr

e

CO

UN

TR

Y M

AP

PIN

G D

ET

AIL

S

W

HO

R

eg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

P

olit

y In

dex

of

Dem

ocra

cy/

Auto

cra

cy

(-10=

fully

auto

cra

tic,

10=

fully

dem

ocra

tic)

Tota

l exp

enditure

in

in

tern

ational

dolla

rs

Public

exp

enditure

in

in

tern

ational

dolla

rs

Out-

of-

pock

et

exp

enditure

in

in

tern

ational

dolla

rs

Angola

A

PO

C,

GA

VI,

GA

EL,

GF

AT

M,

(IP

AA

A),

(V

DP

),

WP

ES

S

US

$ 7

01

5.5

0%

887

197

3.9

0

Pop

ula

tion

=

12.8

m

illio

n

A

PG

R

=

2.9

%<

15–

47.4

%

Life

exp

ecta

ncy

=

40

IM

R

=

15

4/1

00

0

%

<

1$

per

day

=

n/a

Gin

i In

de

x:

n/a

-3

47

28

19

AFRO

Benin

A

MP

, G

AV

I,

GA

ELF

, G

FA

TM

, G

WE

P,

(IP

AA

A),

(L

FI)

, M

VP

, (N

etM

ark

-Plu

s),

R

BM

, (V

DP

)

US

$ 3

68

3.6

1%

1,0

70

36

<1

26

Pop

ula

tion

=

6.4

m

illio

n

AP

GR

=

2.5

%

<15

–

43%

Life

exp

ecta

ncy

=

50.6

IMR

= 9

4/1

00

0

%<

$1/d

ay=

n/a

G

ini

Ind

ex:

n/a

6

39

18

21

Mappin

g G

lobal H

ealth P

art

ners

hip

s

29

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Bots

wa

na

AC

HA

P,

DP

P,

GB

C,

GF

AT

M,

(IP

AA

A),

S

F,

(VD

P)

US

$ 3

06

6 3

9%

48,7

00

224

0

0

Pop

ula

tion

=

1.7

m

illio

n

AP

GR

=

0.2

%<

15

–

40%

Life

exp

ecta

ncy

=

39.7

IMR

= 8

0/1

00

0

%<

$1/d

ay =

G

ni

ind

ex:

=

63

9

213

133

80

Burk

ina F

aso

AM

P,

GA

VI,

GA

EL,

GA

ELF

, G

ET

-202

0,

GF

AT

M,

GW

EP

, (I

PA

AA

),

(LF

I),

SC

I,

SF

, S

tep

Forw

ard

, (V

DP

)

US

$ 2

15

6.5

0%

600

157

0

17

5

Pop

ula

tion

–

12.3

m

illio

n

AP

GR

=

3.0

%<

15–

48.9

%

Life

exp

ecta

ncy

=

45.7

IMR

=

10

4/1

00

0

%<

$1/d

ay

=

61.2

%G

ini

Ind

ex

= 4

8.2

-3

37

12

26

Buru

ndi

AP

OC

, G

AV

I,

GA

EL,

GF

AT

M,

(IP

AA

A),

(V

DP

)

US

$ 9

9

8.9

0%

48,0

90

170

0

0

Pop

ula

tion

=

6.4

m

illio

n

A

PG

R

=

3.1

%

<15

–

47.5

%

Life

exp

ecta

ncy

=

40.9

IM

R

=

11

4/1

00

0

%<

$1/d

ay=

58.4

%G

ini

inde

x =

33.3

-1

26

9

17

Mappin

g G

lobal H

ealth P

art

ners

hip

s

30

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Cam

ero

on

AP

OC

, G

AV

I,

GF

AT

M,

(IP

AA

A),

M

VP

, (N

etM

ark

-Plu

s),

(V

DP

),

SC

I,

WP

ES

S

US

$ 5

99

11.8

0%

290

0

96

0.6

0

Pop

ula

tion

=

15.4

m

illio

n

AP

GR

=

1.4

%<

15–

42.7

%

Life

exp

ecta

ncy

=

46.2

IMR

= 9

9/1

00

0

%<

$1/d

ay=

33.4

%G

ini

inde

x =

47.7

-4

86

17

69

Ca

pe V

erd

e

GA

EL,

(VD

P)

US

$

1,3

17

60

38

22

CA

R

AP

OC

, G

AV

I,

GA

EL,

GF

AT

M,

(IP

AA

A),

M

VP

, (V

DP

),

WP

ES

S

US

$ 2

57

12.9

0%

220

0

255

2

0

Pop

ula

tion

=

3.8

m

illio

n

AP

GR

–1.4

%<

15

–

43%

Life

exp

ecta

ncy

=

39.5

IM

R

=

11

5/1

00

0

%<

$1/d

ay=

66.6

%G

ini

inde

x =

61.3

6

33

23

10

Ch

ad

AP

OC

, G

AV

I,

GF

AT

M,

(IP

AA

A),

M

VP

, (N

etM

ark

-Plu

s),

(V

DP

),

SC

I,

WP

ES

S

US

$ 2

02

3.6

1%

197

168

0

0

Pop

ula

tion

=

8.1

m

illio

n

AP

GR

=

2.9

%<

15–

46.6

%

Life

exp

ecta

ncy

=

44.7

IM

R

=

11

7/1

00

0

%<

$1/d

ay=

n/a

Gin

i in

de

x: n

/a

-2

35

28

7

Mappin

g G

lobal H

ealth P

art

ners

hip

s

31

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Com

oro

s

GA

VI,

GA

EL,

GF

AT

M,

(IP

AA

A),

(V

DP

)

US

$ 3

86

0

47

32

15

Co

ng

o

AP

OC

, D

PP

, G

AV

I,

(IP

AA

A),

M

NT

, (V

DP

),

WP

ES

S

US

$ 8

96

0

-6

101

37

64

Cote

d’Ivoir

e

GA

VI,

GF

AT

M,

GW

EP

, (I

PA

AA

),

(LF

I),

SF

, (V

DP

),

WP

ES

S

US

$ 6

34

42

%

<$1/d

ay=

12.3

%

4

57

22

35

DR

C

AP

OC

, G

AV

I,

GA

EL,

GF

AT

M,

(IP

AA

A),

S

top

TB

,

(VD

P),

W

PE

SS

US

$ 9

9

4.9

0%

296

0

184

1

0

Pop

ula

tion

=

49.8

m

illio

n

A

PG

R

=

2.8

%<

15–

46.8

%

Life

exp

ecta

ncy

=

41.8

IMR

=

12

9/1

00

0

%<

$1/d

ay=

n/a

Gin

i in

de

x: n

/a

inte

rregn

um

21

1

20

Equitori

al

Guin

ea

AP

OC

, (I

PA

AA

),

(VD

P)

0

-5

89

51

38

Mappin

g G

lobal H

ealth P

art

ners

hip

s

32

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Eri

trea

RB

M,

GA

VI,

GA

EL,

GF

AT

M,

(IP

AA

A),

(V

DP

)

US

$ 1

64

2.8

0%

347

9

249

0

Pop

ula

tion

=

3.8

m

illio

n

A

PG

R

=

3.1

%<

15-

45.7

%

Life

exp

ecta

ncy

=

52.7

IMR

= 7

2/1

00

0

%<

$1/d

ay=

n/a

Gin

i in

de

x: n

/a

-6

24

13

11

Eth

iopia

A

PO

C,

DO

O,

GA

VI,

GE

T-

202

0,

GW

EP

, G

FA

TM

, (I

PA

AA

),

ITI,

MN

T,

MV

P,

NetM

ark

-P

lus,

RB

M,

Sto

p

TB

, (V

DP

)

US

$ 9

5

6.4

1%

556

179

13

Pop

ula

tion

=

67.3

m

illio

n

A

PG

R

=

2.4

%<

15–

45.8

%

Life

exp

ecta

ncy

=

45.5

IM

R=

116/1

00

0 %

<$1/d

ay=

81.9

%G

ini

inde

x =

57.2

1

20

7

13

Gabon

AP

OC

, G

FA

TM

, (I

PA

AA

),

(VD

P)

US

$

3,4

97

0

4

196

130

66

Mappin

g G

lobal H

ealth P

art

ners

hip

s

33

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Gam

bia

D

PP

, G

AV

I,

GA

EL,

GF

AT

M,

(IP

AA

A),

(L

FI)

, M

VP

, (V

DP

)

US

$ 2

91

0

-5

52

24

28

Ghana

AM

P,

CF

, D

PP

, G

AE

LF

, G

AV

I,

GB

C,

GE

T-

202

0,

GW

EP

, G

FA

TM

, (I

PA

AA

),

ITI,

(L

FI)

N

etM

ark

-P

lus,

RB

M,

SC

I,

(VD

P).

W

PE

SS

US

$ 2

69

PLA

=

3%

Mala

ria

=

15,3

44/1

00,0

00

TB

=

145/1

00,0

00

15,3

44

145

0.3

8,2

85

Pop

ula

tion

=

20

m

illio

n

AP

GR

=

2.0

%<

15–

40.6

%

Life

exp

ecta

ncy

=

57.9

IMR

= 5

7/1

00

0

%<

$1/d

ay=

44.8

%G

ini

inde

x=39.6

2

45

21

24

Guin

ea

GA

VI,

GF

AT

M,

(IP

AA

A),

(L

FI)

, M

VP

, (V

DP

),

WP

ES

S

US

$ 3

94

0

-1

52

30

22

Mappin

g G

lobal H

ealth P

art

ners

hip

s

34

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Guin

ea-B

isau

GA

VI,

GF

AT

M,

(IP

AA

A),

M

VP

, (V

DP

)

US

$ 1

62

0

6

54

41

13

Kenya

AP

OC

, D

PP

, G

AV

I,

GA

WLF

, G

BC

, G

FA

TM

, H

AC

I,

(IP

AA

A),

M

TC

T-

PLU

S,

(NetM

ark

-Plu

s),

R

BM

, S

CI,

Sto

p

TB

, (V

DP

) W

PE

SS

US

$ 3

71

15%

545

249

0.1

0

0

Pop

ula

tion

=

31.1

m

illio

n

A

PG

R

=

1.2

%<

15–

42.7

%

Life

exp

ecta

ncy

=

44.6

IMR

= 78/1

00

0 %

<$1/d

ay

–

23%

Gin

i in

de

x =

44.5

-2

58

37

21

Lesoth

o

DP

P,

GA

VI,

GF

AT

M,

(IP

AA

A),

S

F,

(VD

P)

US

$ 3

86

0.1

0

in t

ransitio

n

100

73

27

Mappin

g G

lobal H

ealth P

art

ners

hip

s

35

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Lib

eri

a

AP

OC

, G

AV

I,

GF

AT

M,

(IP

AA

A),

(L

FI)

, (V

DP

),

WP

ES

S

N/a

0

0

33

22

11

Mad

ag

ascar

GA

VI,

GF

AT

M,

(IP

AA

A),

(V

DP

)

US

$ 2

88

0

7

108

100

8

Mala

wi

AP

OC

, D

PP

, G

AV

I,

GE

T-

202

0,

GF

AT

M,

HA

CI,

(IP

AA

A),

R

BM

, S

CI,

(VD

P)

US

$ 1

66

15%

25,9

48

242

0.5

0

Pop

ula

tion

=

11.6

m

illio

n

AP

GR

=

1.9

%<

15–

45.9

%

Life

exp

ecta

ncy

=

37.5

IMR

=

11

4/1

00

0

%<

$1/d

ay=

41.7

%G

ini

inde

x =

50.3

7

47

29

18

Mappin

g G

lobal H

ealth P

art

ners

hip

s

36

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Mali

AM

P,

GA

VI,

GE

T-

202

0,

GF

AT

M,

GW

EP

, (I

PA

AA

),

ITI,

(LF

I),

MV

P,

NetM

ark

-P

lus,

SF

, R

BM

, S

CI,

(VD

P)

US

$ 2

39

1.6

5%

400

8

295

0.5

82

4

Pop

ula

tion

=

12.3

m

illio

n

AP

GR

=

3.1

%<

15–

49.2

%

Life

exp

ecta

ncy

=

48.6

IMR

=

14

1/1

00

0

%<

$1/d

ay=

72.8

%G

ini

inde

x =

50.5

6

31

15

16

Mauri

tania

G

AV

I,

GF

AT

M,

GW

EP

, (I

PA

AA

),

MV

P,

(VD

P)

US

36

6

0.3

13

-6

73

22

51

Mozam

biq

ue

AP

OC

, C

F,

DP

P,

GA

VI,

GF

AT

M,

HA

TC

, (I

PA

AA

),

MT

CT

-P

lus,

(NetM

ark

-Plu

s),

S

top

TB

, (V

DP

)

US

$ 2

00

13%

18,1

15

125

3.4

0

Pop

ula

tion

=

18.2

m

illio

n

AP

GR

=

1.5

%<

15-4

4%

Life

exp

ecta

ncy

=

38

IMR

=

12

5/1

00

0

%<

$1/d

ay=

37.9

%G

ini

inde

x =

39.6

6

46

36

10

Mappin

g G

lobal H

ealth P

art

ners

hip

s

37

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Nam

ibia

D

PP

, G

FA

TM

, (I

PA

AA

),

SF

, (V

DP

)

US

$

1,7

30

0

6

311

161

150

Nig

er

GP

EI,

GA

VI,

GF

AT

M,

GW

EP

, IT

I, (

LF

I),

MV

P,

SC

I,

(VD

P)

US

$ 1

75

n/a

169

3

150

0.7

27

9

Pop

ula

tion

=

11.1

m

illio

n

AP

GR

=

3.6

%<

15-

49.9

%

Life

exp

ecta

ncy

=

46.2

IM

R

=

15

6/1

00

0

%<

$1/d

ay=

61.4

%G

ini

inde

x =

50.5

4

27

13

14

Nig

eri

a

AP

OC

, G

AE

LF

, G

AV

I,

GE

T_20

20,

GF

AT

M,

GP

EI,

GW

EP

, H

AT

C,

(IP

AA

A),

(L

FI)

, M

NT

, M

VP

, N

etM

ark

-P

lus,

RB

M,

SC

I,

Sto

p

TB

, (V

DP

),

WP

ES

S

US

$ 3

19

5.8

0%

30

196

0.5

1,4

59

Pop

ula

tion

=

11

7.8

m

illio

n

A

PG

R

=

2.3

%<

15-

44.8

%

Life

exp

ecta

ncy

=

51.5

IMR

=

11

0/1

00

0

%<

$1/d

ay=

70.2

%G

ini

inde

x =

50.6

4

35

10

25

Mappin

g G

lobal H

ealth P

art

ners

hip

s

38

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Rw

anda

AP

OC

, D

PP

, G

AV

I,

GF

AT

M,

HA

TC

, (I

PA

AA

),

MT

CT

-P

lus,

(VD

P)

US

$19

6

0

-4

36

18

18

Sao

Tom

e

&

Pri

ncip

e

GA

VI,

(IP

AA

A),

(V

DP

)

US

$ 3

11

0

45

34

11

Sene

gal

DP

P,

GA

VI,

GF

AT

M,

GP

HW

, H

AT

C,

(IP

AA

A),

(L

FI)

, M

VP

, N

etM

ark

-P

lus,

RB

M,

SF

, (V

DP

)

US

$ 4

76

0

8

72

40

32

Seych

elle

s

(IP

AA

A),

(V

DP

)

0

470

358

112

Mappin

g G

lobal H

ealth P

art

ners

hip

s

39

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Sie

rra L

eo

ne

GA

VI,

GA

EL,

GF

AT

M,

(IP

AA

A),

(L

FI)

, M

TC

T-

Plu

s,

MV

P,

(VD

P),

W

PE

SS

US

$ 1

46

0.7

0%

44,6

95 (

6)

258

3.5

0

Pop

ula

tion

=

4.6

m

illio

n

AP

GR

=

2.4

%<

15-4

4%

Life

exp

ecta

ncy

=

34.2

IMR

= 1

82

%<

$1/d

ay=

57%

Gin

i in

de

x =

62.9

inte

rregn

um

31

3

28

South

Afr

ica

CF

, D

PP

, G

BC

, G

FA

TM

, H

AT

C,

(IP

AA

A),

M

TC

T-

Plu

s,

Sto

p

TB

, (V

DP

)

US

$

2,6

20

0

0

G

ini

inde

x:

59.3

9

367

184

183

Suda

n

AM

P,

AP

OC

, G

AV

I,

GA

EL,

GA

ELF

, G

FA

TM

, G

WE

P,

(IP

AA

A),

IT

I, M

VP

, R

BM

, (V

DP

),

WP

ES

S

US

$ 3

95

2.6

0%

13,9

34

142

0.3

20,2

99

Pop

ula

tion

=

32.2

m

illio

n

AP

GR

=

1.8

%<

15-

39.9

%

Life

exp

ecta

ncy

=

55.6

IMR

= 6

5/1

00

0

N/a

Gin

i in

de

x: n

/a

-7

43

9

34

Mappin

g G

lobal H

ealth P

art

ners

hip

s

40

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Sw

azaila

nd

DP

P,

GA

EL,

GB

C,

GF

AT

M,

(IP

AA

A),

S

F,

(VD

P)

US

$

1,1

75

0

0

119

86

33

Tan

zania

A

PO

C,

DP

P,

GA

VI,

GA

ELF

, G

FA

TM

, H

AT

C,

(IP

AA

A),

IT

I,

RB

M,

SC

I,

Sto

pT

B,

Ste

p

Forw

ard

, (V

DP

),

WP

ES

S, U

S$ 2

71

7.8

3%

1,2

07

212

1.6

0

Pop

ula

tion

=

35.6

m

illio

n

AP

GR

=

1.8

%<

15-

45.6

%

Life

exp

ecta

ncy

=

43.3

IMR

=

10

4/1

00

0

%<

$1/d

ay=

19.9

%G

ini

inde

x =

38.2

2

36

22

14

Tog

o

AM

P,

GA

VI,

GA

ELF

, G

FA

TM

, G

WE

P,

(IP

AA

A),

(L

FI)

, (V

DP

)

US

$ 2

70

0.9

62

2

-2

35

15

20

Mappin

g G

lobal H

ealth P

art

ners

hip

s

41

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

U

gan

da

AM

P,

AP

OC

, D

PP

, G

AV

I,

GA

EL,

GA

ELF

, G

BC

, G

ET

-202

0,

GF

AT

M,

GW

EP

, H

AC

I,

HA

TC

, (I

PA

AA

),

MT

CT

-P

lus,

NetM

ark

-P

lus,

SC

I,

Sto

p

TB

, (V

DP

),

WP

ES

S

US

$ 2

49

5%

46

187

0.3

13

Pop

ula

tion

=

24.2

m

illio

n

AP

GR

=

3.5

%<

15-5

0%

Life

exp

ecta

ncy

=

46.2

IMR

= 7

9/1

00

0

%<

1/d

ay=

82.

2%

Gin

i in

de

x

= 3

7.4

-4

44

17

27

Mappin

g G

lobal H

ealth P

art

ners

hip

s

42

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Zam

bia

D

PP

, G

AV

I,

GA

EL,

GA

ELF

, G

BC

, G

FA

TM

, (I

PA

AA

),

MT

CT

-P

lus,

NetM

ark

-P

lus,

RB

M,

SC

I,

(VD

P)

US

$ 3

54

21.5

2%

34,2

04

445

0.3

0

Pop

ula

tion

=

10.6

m

illio

n

AP

GR

=

1.3

%<

15-

46.4

%

Life

exp

ecta

ncy

=

32

IM

R

=

11

2/1

00

0

%<

1/d

ay=

63.7

%G

ini

inde

x =

52.6

1

59

34

25

Zim

babw

e

DP

P,

CF

, R

BM

, G

AV

I,

GA

ELF

, G

FA

, (I

PA

AA

),

RB

M,

Sto

p

TB

, (V

DP

),

TM

US

$ 7

06

0

0

G

ini

inde

x:

56.8

-5

129

62

67

Afg

ha

nis

tan

GA

VI,

GA

EL,

GF

AT

M,

GP

EI,

Sto

p

TB

, (V

DP

)

N/a

0

P

op

ula

tion

=

22

m

illio

n

IMR

=

16

5/1

00

0

N/a

Gin

i in

de

x: n

/a

-7

28

11

17

EMRO

Bahra

in

U

S$

12,1

89

0.6

519

315

204

Mappin

g G

lobal H

ealth P

art

ners

hip

s

43

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Djib

outi

GA

VI,

(VD

P)

US

$ 8

94

0.4

48

35

13

Egypt

GP

EI,

GA

ELF

, G

FA

TM

, (V

DP

)

US

$

1,5

11

0.3

G

ini

inde

x:

34.4

-6

118

32

86

Iran

GF

AT

M

US

$

1,7

67

0

3

200

86

114

Iraq

N

/a

0

-9

110

65

45

Jord

an

GF

AT

M

0

-2

177

119

58

Kuw

ait

0

-7

605

529

76

Leb

anon

U

S$

3,8

11

0

in

terr

uption

470

167

303

Lib

ya

0

-7

222

120

102

Moro

cco

ITI,

G

FA

TM

, (V

DP

)

US

$

1,1

73

0.1

-6

160

65

95

Om

an

0

-9

302

182

120

Pakis

tan

CF

, G

AV

I,

GE

T-

202

0,

GF

AT

M,

GP

EI,

MN

T,

Sto

p

TB

, (V

DP

)

US

$ 4

15

0.1

1%

58

178

0.1

Pop

ula

tion

=

14

6

mill

ion

AP

GR

=

2.4

%<

15-

41.8

%

Life

exp

ecta

ncy

=

61

IMR

= 8

4/1

00

0

%<

1/d

ay=

13.4

%G

ini

inde

x =

33

-6

71

16

55

Pale

stine

0

0

Qata

r

0

110

5

635

470

Saudi A

rabia

0

-1

0

332

297

35

Mappin

g G

lobal H

ealth P

art

ners

hip

s

44

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Som

alia

G

FA

TM

, M

NT

, (V

DP

)

0.4

11

8

3

Syri

a

0

-7

109

37

72

Tunis

ia

0

-3

227

100

127

UA

R

0

0

Yem

en

GA

VI,

GA

ELF

, G

FA

TM

US

$ 5

14

0.2

G

ini

inde

x:

33.4

-2

32

12

20

Bangla

desh

CF

, G

AV

I,

GA

EL,

GA

ELF

, G

FA

TM

, M

NT

, S

top

TB

, (V

DP

)

US

$ 3

50

<.1

%

40

211

0.5

Pop

ula

tion

=

14

0.9

m

illio

n

AP

GR

=

1.8

%<

15-

38.8

%

Life

exp

ecta

ncy

=

61.4

IMR

= 5

1/1

00

0

%<

$1/d

ay=

36%

Gin

i in

de

x =

31.8

6

70

32

38

Bhuta

n

GA

VI

US

$ 6

44

0.2

-8

82

38

44

SEARO

DP

R K

ore

a

GA

VI

0.1

-9

39

33

6

Mappin

g G

lobal H

ealth P

art

ners

hip

s

45

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

India

C

F,

GA

VI,

GB

C,

GE

T-

202

0,

GP

EI,

GP

HW

, G

AE

LF

, G

FA

TM

, M

NT

, S

tep

Forw

ard

, S

top

TB

, (V

DP

)

US

$46

2

0.7

9%

7

199

3.3

Pop

ula

tion

=

1,0

33

mill

iion

AP

GR

=

1.3

%<

15-

33.7

%

Life

exp

ecta

ncy

=

63.9

IM

R=

67.5

/10

00

%<

$1/d

ay=

34.7

%G

ini

inde

x =

37.8

9

82

11

71

Indo

nesia

C

F,

GA

VI,

GA

ELF

, G

FA

TM

, S

top

TB

, (V

DP

)

US

$ 6

95

0.1

0%

920

321

0.8

Pop

ula

tion

=

21

4

mill

ion

AP

GR

=

1.1

%<

15-

30.4

%

Life

exp

ecta

ncy

=

66.8

IMR

= 33/1

00

0 %

<$1/d

ay=

7%

Gin

i in

de

x

= 3

0.3

7

47

21

26

Mald

ives

(VD

P)

US

$

2,0

82

0.6

249

159

90

Mya

nm

ar

CF

, G

AV

I,

GA

ELF

, G

FA

TM

, S

top

TB

, (V

DP

)

N/a

0.6

-7

79

10

69

Mappin

g G

lobal H

ealth P

art

ners

hip

s

46

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Ne

pal

GA

VI,

GA

ELF

, G

ET

-202

0,

GF

AT

M,

GP

HW

, IT

I,

(VD

P)

US

$ 2

36

3

6

41

11

30

Sri

Lanka

CF

, G

AV

I,

GF

AT

M,

(VD

P)

US

$ 8

49

0.9

5

75

35

40

Thaila

nd

CF

, G

BC

, G

FA

TM

, H

AT

C,

MT

CT

-P

lus,

Sto

p

TB

, (V

DP

)

US

$

1,8

74

0.3

9

322

108

214

Tim

or-

Leste

G

FA

TM

0

Bru

nei

857

348

509

WPRO

Cam

bo

dia

C

F,

DP

P,

GA

VI,

GA

EL,

GF

AT

M,

Sto

p

TB

, (V

DP

)

US

$ 2

78

2.7

0%

476

560

0.5

Pop

ula

tion

=

13.5

m

illio

n

A

PG

R

=

2.2

%<

15-

42.5

%

Life

exp

ecta

ncy

=

57.4

IMR

= 9

7/1

00

0

%<

$1/d

ay=

n/a

Gin

i in

de

x

= 4

0.4

2

73

7

66

Mappin

g G

lobal H

ealth P

art

ners

hip

s

47

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Chin

a

CF

, G

AV

I,

GA

EL,

GB

C,

GF

AT

M,

GP

HW

, S

top

TB

, (V

DP

)

US

$ 9

11

0.1

1%

1

107

0

P

op

ula

tion

=

1,2

85

mill

ion

A

PG

R

=

0.6

%%

<1

5-

24.3

%

Life

exp

ecta

ncy

=

71

IM

R =

31/1

00

0 %

<$1/d

ay=

16.1

%G

ini

inde

x =

40.3

-7

73

18

55

Co

ok Isla

nds

GA

ELF

344

264

80

Fed.

Mic

ronesia

234

216

18

Fiji

G

AE

LF

U

S$

2,0

61

in

tra

nsitio

n

214

148

66

Guam

0

Lao P

DR

G

AV

I,

GF

AT

M,

(VD

P)

US

$ 3

26

-7

53

33

20

Mars

hall

Isla

nds

(VD

P)

238

177

61

Mon

golia

(V

DP

)

10

59

56

3

Papu

a

New

G

uin

ea

GA

EL,

GF

AT

M,

(VD

P)

US

$ 5

63

10

76

59

17

Mappin

g G

lobal H

ealth P

art

ners

hip

s

48

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Phili

ppin

es

CF

, G

AE

L,

GA

ELF

, G

FA

TM

, S

top

TB

, (V

DP

)

US

$ 9

12

<.1

%

15

226

0.4

Pop

ula

tion

=

77.2

m

illio

n

AP

GR

=

1.6

%<

15

-37/1

%

Life

exp

ecta

ncy

=

70

IMR

= 2

9/1

00

0

%<

$1/d

ay=

14.6

%G

ini

inde

x =

46.1

8

97

48

49

Re

pu

blic

K

ore

a

U

S$

8,9

17

8

696

325

371

Vanu

atu

G

AE

LF

, (V

DP

) U

S$

1,0

58

85

55

30

Vie

tnam

C

F,

GA

VI,

GA

EL,

GA

ELF

, G

FA

TM

, IT

I,

Sto

p

TB

, (V

DP

)

US

$ 4

11

0.3

0%

95

93

0.1

Pop

ula

tion

=

79.2

m

illio

n

AP

GR

=

1.9

%<

15-

32.6

%

Life

exp

ecta

ncy

=

69.2

IMR

= 30/1

00

0 %

<$1/d

ay=

17.7

%G

ini

inde

x =

36.1

-7

65

13

52

Arg

entin

a

CF

, G

AE

L

US

$

7,1

16

8

741

473

268

Baham

as

HA

TC

118

5

614

571

PAHO

Beliz

e

CF

, G

FA

TM

U

S$

3,2

58

212

109

103

Mappin

g G

lobal H

ealth P

art

ners

hip

s

49

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Boliv

ia

CF

, G

FA

TM

, G

AV

I,

(VD

P)

US

$ 9

36

0.1

0%

378

116

Pop

ula

tion

=

8.5

m

illio

n

AP

GR

=

1.5

%<

15-

39.3

%

Life

exp

ecta

ncy

=

63.9

IMR

= 6

0/1

00

0

%<

$1/d

ay=

14.4

%G

ini

inde

x= 4

4.7

9

142

90

52

Bra

zil

CF

, S

top

TB

, (V

DP

)

US

$

2,9

15

4.1

8

403

208

195

Chile

C

F,

GA

EL,

GF

AT

M

US

$

4,3

14

9

567

285

282

Colo

mbia

C

F,

GA

EL,

GF

AT

M,

(VD

P)

US

$

1,9

15

7

407

276

131

Costa

Ric

a

GF

TA

M

US

$

4,1

59

10

486

377

109

Cu

ba

GF

TA

M,

(VD

P)

-7

110

96

14

Dom

inic

an

Re

pu

blic

G

AE

L,

GA

ELF

, G

FA

TM

, H

AT

C,

(VD

P)

US

$

2,4

94

2.5

0%

6

88

Pop

ula

tion

=

8.5

m

illio

n

A

PG

R

=

1.3

%<

15-3

3%

Life

exp

ecta

ncy

=

66.7

IMR

: 44/1

000

%<

$1/d

ay=

<

2%

Gin

i in

de

x= 4

7.4

8

152

78

74

Mappin

g G

lobal H

ealth P

art

ners

hip

s

50

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Ecuador

CF

, G

AE

L,

GF

AT

M,

(VD

P)

6

170

98

72

El S

alv

ador

CF

, G

FA

TM

, (V

DP

)

US

$

2,1

47

7

228

85

143

Guate

mala

C

F,

GF

AT

M,

(VD

P)

8

81

55

26

Guya

na

GA

EL,

GF

AT

M,

(VD

P)

US

$ 9

12

6

129

103

26

Haiti

CF

, D

PP

, G

AV

I,

GA

ELF

, G

FA

TM

, H

AT

C,

(VD

P)

US

$ 4

60

6.1

0%

15

190

Pop

ula

tion

=

8.1

m

illio

n

AP

GR

=

1.3

%<

15-

39.8

%

Life

exp

ecta

ncy

=

49.5

IM

R: 79/1

000

%<

$1/d

ay=

n/a

Gin

i in

de

x= n

/a

-2

52

18

34

Ho

nd

ura

s

CF

, G

AV

I,

GF

AT

M,

(VD

P)

US

$ 9

70

7

150

56

94

Jam

aic

a

CF

, G

FA

TM

, (V

DP

)

9

169

120

49

Mexi

co

CF

, G

AE

L

US

$

6,2

14

8

394

172

222

Nic

ara

gua

GF

AT

M,

(VD

P)

8

140

80

60

Mappin

g G

lobal H

ealth P

art

ners

hip

s

51

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Panam

a

GF

AT

M

US

$

3,5

11

9

449

332

117

Para

gu

ay

CF

, G

AE

L,

GF

AT

M,

(VD

P)

7

187

73

114

Peru

C

F,

GF

AT

M,

GP

HW

, (V

DP

)

US

$

2,0

51

in

tra

nsitio

n

221

98

123

Puert

o R

ico

0

Suri

nam

e

GF

AT

M,

(VD

P)

256

87

169

Trinid

ad/T

ob

U

S$

6,7

52

10

314

190

124

Uru

gua

y

US

$

5,5

54

10

354

172

182

Vene

zuela

C

F

US

$

5,0

73

7

298

201

97

Alb

ania

G

AV

I,

(VD

P)

US

$

1,3

00

5

63

49

14

Arm

enia

G

AV

I,

GF

AT

M,

(VD

P)

US

$ 5

56

0.1

5%

4

47

Pop

ula

tion

=

3.1

m

illio

n

AP

GR

=

0.3

%<

15:

22.5

%

Life

exp

ecta

ncy

=

72

IM

R =

31/1

00

0

5

152

63

89

EURO

Azerb

aija

n

GA

VI,

(VD

P)

US

$ 6

88

-7

48

38

10

Mappin

g G

lobal H

ealth P

art

ners

hip

s

52

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Georg

ia

GA

VI,

GF

AT

M,

(VD

P)

US

$ 5

94

5

94

8

86

Kyrg

yzsta

n

GA

VI,

GF

AT

M,

(VD

P)

US

$ 3

08

<.1

%

0

88

Pop

ula

tion =

5

m

illio

n

AP

GR

=

1.2

%<

15:

35.4

%

Life

exp

ecta

ncy

=

68.6

IMR

= 5

2/1

00

0

%<

$4/d

ay=

88%

Gin

i in

de

x= 2

9

-3

66

46

20

Mold

ova

GA

VI,

GF

AT

M,

(VD

P)

US

$ 3

46

7

133

100

33

Tajik

ista

n

GF

AT

M,

(VD

P)

US

$ 1

69

<.1

%

303

83

Pop

ula

tion

=

6.1

m

illio

n

A

PG

R

=

1.2

%<

15:

38.5

%

Life

exp

ecta

ncy

=

68.8

IMR

= 5

3/1

00

0

N/a

Gin

i in

de

x= 3

4.7

-1

93

82

11

Turk

menis

tan

GA

VI,

(VD

P)

US

$

1,0

97

90

77

13

Ukra

ine

GA

VI,

GF

AT

M,

(VD

P)

US

$ 7

66

7

127

96

31

Mappin

g G

lobal H

ealth P

art

ners

hip

s

53

DF

ID H

ealth R

esourc

e C

entr

e

WH

O

Reg

ion

C

ou

ntr

y

GH

Ps

(1)

GD

P

per

cap

ita (

2)

Pers

on

s

Liv

ing

w

ith

A

IDS

%

p

op

ula

tio

n

Mala

ria

per

100,0

00

TB

p

er

100,0

00

Lep

rosy

per

10,0

00 (

3)

Gu

inea

Wo

rm #

of

ca

se

s

rep

ort

ed

20

03 (

4)

Dem

og

rap

hic

D

ata

P

overt

y

Data

P

oliti

cal

Ch

ara

cte

risti

c

(5)

Healt

h S

yste

m C

hara

cte

risti

cs (

6)

Uzbekis

tan

GA

VI,

GF

AT

M,

(VD

P)

US

$ 4

50

<.1

%

1

63

Pop

ula

tion

=

25.3

m

illio

n

AP

GR

=

1.4

%<

15-

35.4

%

Life

exp

ecta

ncy

=

69.7

IM

R =

52/1

00

0

N/a

Gin

i in

de

x= 2

6.8

-9

109

88

21



Key to GHP Mapping Tables *A GHP in brackets covers the country but does not necessarily operate in it at present (1) GHP information was provided from individual GHP websites. Therefore the

information is only as accurate and up to date as the websites are themselves. (2) All figures and definitions are from the UNDP’s Human Development Report

2003, unless otherwise stated.

GDP =.GDP converted to US dollars using the average official exchange rate reported by the International Monetary Fund. An alternative conversion factor is applied if the official exchange rate is judged to diverge by an exceptionally large margin from the rate effectively applied to transactions in foreign currencies and traded products. Epidemiological information: PLA = Estimated percentage of Adults between the ages of 15 and 45 living with AIDS at the end of the year. Malaria figures represent total number of cases report by the country to the WHO, divided by the total population and then multiplied by 100,000 to give a comparison rate. A similar calculation is made for TB (tuberculosis) to provide a TB case rate.

Demographic Data: All population figures are 2001 estimates. APGR = Annual Population Growth Rate – the APGRs presented here are the estimated ones for 2001-2015. %<15 is the Percentage of the Population aged less than 15 in 2001. Poverty data: Population below income poverty line - This is set of < US$ 1 per day for low and some medium income countries. For OECD, CIS and CCE countries this is set at a series of levels, including <US$ 4/day, or the national poverty line. A further indicator of the distribution of income is the Gini index. The Gini index is used to measure the extent to which income distribution between individuals and families in a country deviates from equal distribution. A ‘0’ represents perfect equality while ‘100’ represents perfect inequality. To put this into context, the Gini index for the Nordic countries is around 25. For the US it is 40.8, and for the UK it is 36.

(3) Leprosy prevalence: information was provided by ILEP (International Leprosy

Eradication Partners) 2002/2003 annual report, available on their website. (4) Guinea Worm cases: information was provided by the Guinea Worm Eradication

Programme’s website. (5) Political system: Measures of polity taken from EarthTrends 2003 report, which

provides information on the degree of democracy in individual countries. (EarthTrends Data Tables: Environmental Governance and Institutions)

(6) Health Systems information: Public v Private – based on data presented in the

World Health Report 2000 Table 8 – National Health Accounts (7) Sierra Leone malaria prevalence: Provided by the Statistics for Sierra Leone

website, relating to 2002 prevalence.



APPENDIX C – DFID INTEREST 1. Classification of the 19 GHPs of interest to DFID – international level P = primary role; S – secondary role

GHP Research and

development

International and National Advocacy

Financing Technical support, service delivery, donations and discounted products

APOC S S P

DNDi P S P

GAEL S P

GAELF S P

GAVI S P S

GFATM S P S

GPEI S S P

GWEP S P S

IAVI P S

IPM P

ITI S P

MDP 2* P

MIM P S

MMV P

MVI P S

RBM P S

SCI S P S

Stop TB S P

WPESS S P

* Microbicides Development Programme



2. Classification of GHPs involved in HIV/AIDS, Malaria and TB

GHP Research and development

International and national advocacy

Financing Technical support, service delivery, donations and discounted products

HIV/AIDS CICCR

CONRAD

GMP

IAVI

IPM

HTVN

MDP (2)

GBC

GCM

GCWA

GMAI

GRI

GFATM AAI

ACHAP

CF

DPP

HACI

HATC

IPAAA

MTCTPlus

SF

Step Forward

VDP

Malaria Artesunate

DNDi

EMVI

JPMW

MIM

MMV

MVI

LAPDAP

TROPIVAL

Roll Back Malaria GFATM AMP

Coartem

NetMark Plus

TB Aeras

FIND

GATBDD

TROPIVAL

Global Partnership to Stop TB

GFATM EL-MDRTBP

GLC

GDF

mapping global health partnerships what they are, what

Documents